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Prostate cancer is the most common non-skin cancer type in American males. 
Poor diet quality may have profound negative consequences on disease outcome. 
Diets consisting of low cruciferous vegetable and high red meat intake were found to 
be significant, yet modifiable risk factors. Currently, there are no effective cures for 
prostate cancer. As a result, improved diet quality through the promoted use of 
natural products is commonly sought after complementary health approach to disease 
prevention and cancer risk reduction. Phenethyl isothiocyanate (PEITC) and indole-3-
carbinol (I3C), naturally occurring bioactive compounds in cruciferous vegetables, 
are considered ideal chemopreventive candidates. 
This dissertation focused on examining biological efficacy and identifying 
distinctive biological mechanisms utilized by PEITC and I3C to modulate human 
prostate cancer growth in a xenograft mouse model.  
When treated with PEITC, mice were found to be differentially responsive. 
Tissue analysis revealed a significant decrease in tumor burden with no observable 
toxic effects. PEITC exerted minimal effects on androgen responsive pathways within 
tumors. However, cell proliferation and macrophage presence were significantly 
  
reduced and insulin-like growth factor binding protein-3 expression was increased in 
the treatment group fed PEITC.  
Previous studies have shown an overlap in no effect and chemopreventive I3C 
dosage levels. Therefore, physiological and biological sensitivity to I3C in a 
commonly used xenograft model was examined. Mice were biologically responsive to 
doses exceeding 10 µmoles I3C/g diets. Viability was significantly affected at the 
highest concentration unless mice were switched to the control diet without I3C after 
first detection of stress. The intestine appeared to be the target of I3C toxicity as 
noted by changes in number and width of intestinal villi, proliferation, and apoptosis. 
Changes to xenobiotic metabolism were indicated within the livers of the treatment 
mice, supporting involvement of aryl hydrocarbon receptor-mediated pathway in the 
metabolism of I3C. 
Biological efficacy of low, physiologically relevant doses of I3C was also 
examined. Following exposure to low concentrations of I3C, tumor volume, 
xenobiotic metabolism, and cell motility were altered in tumorigenic mice.  
Collectively, findings from this study highlighted unique, yet complicated, 
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Prostate cancer (PCa) is one of the leading causes of cancer-related deaths in 
American males. Factors associated with prostate cancer onset include age, genetics, 
and diet. Poor diet quality may drastically affect disease outcomes. Diets consisting of 
low cruciferous vegetables and high red meat intake were found to be significant, yet 
modifiable risk factors. Currently, there are no effective cures for PCa. As a result, 
improved diet quality and promoted use of natural products are commonly sought 
after as complementary health approaches to disease prevention and risk reduction. 
Phenethyl isothiocyanate (PEITC) and indole-3-carbinol (I3C), naturally occurring 
bioactive compounds in cruciferous vegetables, are considered ideal chemopreventive 
candidates. 
This project focuses on identifying distinctive mechanisms of PEITC and I3C 
to modulate human prostate cancer growth. Three specific aims of this study 
addressed the biological mechanisms and efficacy of PEITC and I3C in a xenograft 
mouse model. The first aim of this study investigated the effects of PEITC along the 
macrophage axis and the insulin-like growth factor-1 pathway. Previous studies have 
shown an overlap in no effect and chemopreventive I3C dosage levels. Therefore, the 
second aim of this project was designed to assess for physiological and biological 
sensitivity to I3C in a commonly used xenograft model. Utilizing the same animal 
model, the final aim addressed the biological efficacy of low, yet physiologically 
relevant doses of I3C.  
Findings from this study highlighted unique, yet complicated, pleiotropic 





Chapter 1: Literature Review 
Chronic Disease 
Chronic diseases are long-lasting conditions that are generally slow to manifest 
and progress (Goodman, Posner, Huang, Parekh, & Koh, 2013). Monitoring and 
evaluating changes in mortality patterns has been crucial in the assessment of health 
status and well being in our nation. Age and sex are commonly identified as variables 
in mortality patterns and drivers in the likelihood of developing certain chronic 
diseases. In the United States, cardiovascular disease, malignant neoplasms, diabetes 
mellitus, and cerebrovascular diseases such as stroke are among the leading causes of 
death and contribute to greater than 50% of all deaths (Heron, 2013). Due to medical 
advances, mortality rates for heart disease and cancer are gradually declining; 
however, incidence rates of these two, amongst other chronic diseases, are steadily 
rising (Heron, 2013; "On the Rise Globally, Cancer Mortality Declines in U.S.," 
2014).  
Cancer, a general name given to more than 100 diseases, marks the development 
of abnormal and malignant cell growth within the body. A 2012 GLOBOCAN review 
of worldwide cancer incidence, mortality, and prevalence (within 5 years of 
diagnosis) projected 14.1 million new cancer cases, 8.2 million cancer-related deaths, 
and estimated 32.6 million were living with cancer. Overall age standardized cancer 
incidence rate (ASR) is 25% higher in men than women (International Agency for 
Research on Cancer, 2013). As of January 2012, approximately 13.7 million U.S. 
citizens were living in America with a history of cancer and approximately 1.7 
million new cases, excluding carcinoma in situ, are expected to be diagnosed this 
year, as reported by the American Cancer Society (American Cancer Society, 2014). 
This dissertation focuses on prostate cancer, a male prominent cancer type, with 
the intent of studying the barriers to finding a cure as well as possible means of 
successful prevention. 
Chronic disease management takes a heavy toll on the economy. The cost 




cost but also on a personal level by coping with severe disabilities, such as chronic 
neuropathic pain for those experiencing cancer.  In 2012, the American Public Health 
Association reported heart disease, cancer, lung ailments, diabetes, and hypertension, 
as the top five most costly yet preventable diseases, which accounted for 
approximately $327 billion dollars or 30% of the total health spending nationwide. 
National Cancer Institute (NCI) 2020 cost projections for all sites of cancer in males 
were $6.6 billon dollars, a 35.6% increase from 2010 in initial costs of care. 
Likewise, initial costs of care for specific types such as prostate cancer, are expected 
to increase 51% by 2020.  
CDC reports common causes of the growing epidemic of chronic disease as 1) 
lack of physical activity; 2) poor nutrition; 3) tobacco use; and 4) excessive alcohol 
consumption (Centers for Disease Control and Prevention, 2012). These modifiable 
risk factors heavily contribute to the development of the secondary illness & 
comorbidity, suffering, and decreased life expectancy associated with chronic disease. 
Thus, there is a critical need for effective public health interventions that target 
chronic disease, to promote a healthier population, and improve quality of life.   
Prostate Cancer and Chronic Inflammation 
Prostate Cancer 
Prostate cancer (PCa) is the most common type of non-skin cancer and the 
second leading cause of cancer-related deaths in males (R. L. Siegel, Miller, & Jemal, 
2015). In 2013, approximately 239,000 new cases and 30,000 deaths were projected 
to occur (Edwards et al., 2013). Prostate cancer is within the top 5 commonly 
diagnosed cancers and the fifth leading cause of cancer-related deaths in the world 
(International Agency for Research on Cancer, 2013). GLOBOCAN estimates that 
nearly 1.1 million men worldwide were diagnosed with PCa in 2012.  
Common risk factors for prostate cancer include diet quality, inflammation of 
the prostate, weight classification (underweight, overweight, or obese status), age, 
race/ethnicity, nationality, family history, and genetic susceptibility. According to 




(Caribbean, 29 per 100,000 and sub-Saharan Africa, ASRs 19-24 per 100,000) and 
very low amongst Asian populations (2.9 per 100,000 in South-Central Asia) 
(International Agency for Research on Cancer, 2013). Rates are intermediate in the 
American regions (International Agency for Research on Cancer, 2013). In the U.S., 
the probability of developing invasive prostate cancer throughout an individual’s 
lifetime is approximately 15% or 1 out of 7 males (DeSantis et al., 2014; R. L. Siegel 
et al., 2015). Moreover, prostate cancer incidence are disproportionately high in 
African Americans (230.8 per 100,000) and Caucasians (142.8 per 100,000) as 
compared to rates of Asian Americans or Pacific Islanders (79.7 per 100,000) (R. 
Siegel, Naishadham, & Jemal, 2012). 
Exact mechanisms yielding to the transition from normal to cancerous prostate 
cancer cells are complicated and remain unclear. Somatic and acquired gene 
mutations are several reasons for the development of prostate cancer. These inherited 
gene mutations may contribute to up to 10% of prostate cancers ("Prostate Cancer: 
Do we know what causes prostate cancer?," 2014). Although, overall inherited DNA 
mutations contribute to a small amount of prostate cancer incidences, primary genes 
correlated with the increased susceptibility of PCa include Hereditary Prostate Cancer 
Gene 1 (HPCG1), Breast Cancer, Early Onset (BRCA) -1 and -2 (Agalliu et al., 
2007). Underlying mechanisms for the acquired mutations include invading, and 
ultimately overriding DNA checkpoints during the cell replication process. Numerous 
factors that may contribute to the regulation of the cell replication process, checkpoint 
failures, and the replication of DNA mutations means that understanding and 
combatting this disease is increasingly difficult. 
To date, there are no effective cures for PCa. Like other epithelial derived 
carcinomas, PCa has a higher survival rate than other adenocarcinomas. However, 
factors affecting prognosis include age, underlying health conditions, metastasis, 
morphology, and detection time. According to the American Cancer Society, men 
should undergo screening for prostate cancer by age 50 or 45 for African Americans 
and other higher risk populations. Two standard tests include the digital rectal exam 
(DRE) and prostate specific antigen (PSA) blood test, which was considered a gold 




et al., 2014; Edwards et al., 2013; Rodrigues et al., 2014; M. C. Wang et al., 1981). In 
general, high levels of PSA have been correlated with cancer incidence. However, 
benign conditions such as an enlarged and inflamed prostate can raise PSA levels and 
therefore cannot be used as a sole determinant for prostate cancer. The treatment of 
prostate cancer is complex and varies due to the disease etiology. Current methods 
used in the treatment of prostate cancer include surgery, radiation therapy, 
cryosurgery, and hormonal and chemotherapy.  
All in all, there are various pathways and biomarkers involved in the initiation 
and progression of prostate cancer. Many of these pathways play an intricate and 
integral role in the regulation of cell properties and functions such as cellular division, 
differentiation, hormonal homeostasis, inflammation, immunity, compound 
activation, apoptosis, and proliferation (World Cancer Research Fund, 2007). As a 
result, diet and hormone levels may influence the rate in which these changes occur. 
Diet, as a modifiable risk factor, is an essential component in prostate cancer 
development and the regulation of secondary risk factors such as chronic 
inflammation (Arab et al., 2013; Gonzales et al., 2014).  
Therefore, my research focuses specifically on evaluating prostate cancer-
related endpoint biomarkers to elucidate antiproliferative regulatory mechanisms 
associated with cruciferous vegetable intake. 
 
Chronic Inflammation 
Inflammation is a protective mechanism that attenuates insults incurred in 
response to internal or external environmental stimulus within a host defense system. 
Persistent or chronic inflammation can prove harmful and may incite disease. In a 
review conducted by Aggarawal et al, chronic inflammation was a noted cause of 
cellular dysfunction and has been implicated in the promotion of chronic diseases 
such as cancer, diabetes mellitus, cardiovascular, pulmonary, and neurological 
diseases (Aggarwal, Shishodia, Sandur, Pandey, & Sethi, 2006). Moreover, the 
diagnosis of inflammation and its biomarkers are not fully understood. However, the 




inflammatory enzymes have been linked with chronic inflammation (Aggarwal et al., 
2006).  
Cancer-driven Inflammation 
Chronic inflammation is a well-known risk factor for most cancers (Anand et 
al., 2008). It has been linked to various steps in tumorigenesis including cellular 
transformation, promotion, survival, proliferation, invasion, angiogenesis, and 
metastasis (Coussens & Werb, 2002; Mantovani, 2005). Inflammation plays a critical 
role within the prostate cancer microenvironment and exacerbates growth as a result 
of its close proximity to cancer sites.  The National Institutes of Health (NIH) issued a 
consensus statement to clinically define prostatic inflammation (Krieger, Nyberg, & 
Nickel, 1999). Class III prostatitis is characterized as a state of chronic, intermittent 
inflammation (Krieger et al., 1999). As one of the most common forms, Class III 
prostatitis is detected in 90% of prostate cancer cases (Hua & Schaeffer, 2004; Lu, 
Ouyang, & Huang, 2006).  
The tumor microenvironment encompasses an assortment of malignant and 
nonmalignant cell populations. Non-malignant populations consist of stromal cells, an 
expanding vasculature, and a leukocyte infiltrate. Macrophages comprise the 
dominant portion of the leukocyte population (Tarin, 2012). 
The influence of macrophages have been studied in carcinoma cell lines (B. 
Wang et al., 2011). Notable findings indicate the presence of tumor associated 
macrophages in benign prostatic conditions such as prostatitis, prostatic hyperplasia, 
prostatic intraepithelial neoplasia (PIN) and proliferative inflammatory atrophy (PIA) 
(De Marzo, Marchi, Epstein, & Nelson, 1999). PIN is characterized as dysplasia of 
the prostate epithelial lining. Both PIA and PIN are considered precursors of prostate 
cancer and with characteristically high expression levels of inflammatory mediators 
(De Marzo et al., 2003). Molecular stress indicated in these conditions increase the 
likelihood of inflammatory cell invasion and inflammatory-mediated onset of prostate 
carcinogenesis (De Marzo et al., 2004).  
Microvesicles have been connected to cancer progression since the 1970’s 




shedding in the promotion of cancer growth and metastasis was examined. Findings 
from these studies provided a mechanism: microvesicles shed from cancer cells and 
fuse to macrophages and other cells in the tumor microenvironment. Once enveloped 
into the cell, the miRNAs released from the microvesicles may bind to toll-like 
receptors (TLRs) and cause host cells to release pro-inflammatory cytokines, which 
facilitate tumor invasion and metastasis (Aggarwal et al., 2006; Fabbri, Paone, 
Calore, Galli, & Croce, 2013; Fabbri et al., 2012). Moreover, circulating miRNAs 
have been correlated with tumor progression in prostate cancer and may have a high 
clinical relevance as a potential biomarker in the early detection of cancers (Brase et 
al., 2011; Schwarzenbach, Nishida, Calin, & Pantel, 2014). Moreover, decreasing 
microvesicle density within tumor microenvironments through dietary intervention 
has been a priority interest among cancer prevention and immunology researchers. 
Cytokines, anti-inflammatory and pro-inflammatory, have a major role in 
regulating biological responses including the regulation of apoptosis and suppression 
of proliferation, angiogenesis, invasion, and metastasis in prostate cancer. These 
genes include TNF, IL-1β, IL-6, IL-8, IL-18, chemokines, MMP-9, and VEGF. The 
expression of these genes is predominantly regulated by the transcription factor NF-
κΒ. NF-κΒ is constitutively active in most tumors and is induced by xenobiotics 
including carcinogens, tumor promoters, chemotherapeutic agents, radiation and 
carcinogenic viral proteins (Aggarwal & Shishodia, 2006; Aggarwal et al., 2006).  
Increased levels of cytokines have been found in blood, ascites, pleural 
effusions, and urine of individuals with cancer (Dunlop & Campbell, 2000). 
Interestingly, no single cytokine has been shown to be present in all individuals with 
cancer and the absence of clinically detectable cytokine levels does not exclude the 
possibility that they play a role in systemic effects (Dunlop & Campbell, 2000; 
Todorov et al., 1996). Moreover, crosstalk amongst cytokines like IL-6 with growth 
factor mediators such as IGFBP3 is possible (Hudson et al., 2012).  Inflammation 
may lead to DNA damage directly or indirectly through crosstalk along other 
pathways, which may promote a tumorigenic environment within a cell. 
In addition to inciting the tumor microenvironment, cytokine accumulation 




related cachexia in more advanced cancers. Cytokines have been shown to affect 
gastric motility and emptying by altering the signals that control satiety (Argilés, 
Moore-Carrasco, Busquets, & López-Soriano, 2003; Argilés, Moore-Carrasco, Fuster, 
Busquets, & López-Soriano, 2003). Consuming vegetables high in anti-inflammatory 
agents such as I3C and PEITC plays a critical role in reducing adverse health effects 
by suppressing NF-κΒ and NF-κΒ - regulated products and should be considered 
candidates in both the prevention and treatment of cancer (Aggarwal & Shishodia, 
2006; Aggarwal et al., 2006) 
Role of Diet in Prostate Cancer Development 
The impact of diet quality on health has been an on-going issue in America. 
With overwhelming support indicating that Americans, males especially, are at risk of 
low vegetable intake, diet modification is a particularly novel application to improve 
nutritional status and thus, decrease the rate of individuals undergoing more advanced 
medical treatment. Nutritional recommendations for cancer patients, specifically 
those with hormonal cancers, should be cautionary as some dietary manipulation of 
certain macro-, micronutrients, and phytochemicals can stimulate tumor growth 
(Gonzales et al., 2014; Langen et al., 1993). However, overall intake of varied 
vegetables along with the reduction of red meat intake has been shown to improve 
prostate health (Michaud et al., 2001). One reason cruciferous vegetable intake 
counterbalances prostate cancer development may be due to their unique composition 
of biological compounds, which will be discussed in later sections. 
Epidemiological, clinical, and preclinical studies have been vital in the 
assessment of diet quality in prostate cancer development. In an epidemiological 
literature review by Kristal and Lampe, studies indicate modest to strong support for 
the hypothesis that a high intake of Brassica vegetables reduces prostate cancer risk 
(Jain, Hislop, Howe, & Ghadirian, 1999; Kolonel et al., 2000; Kristal & Lampe, 
2002). Moreover, in a population-based case-control study of men under 65 years of 
age indicated that consuming three or more servings of cruciferous vegetables per 
week was a significant factor in decreasing prostate cancer cases as compared to that 




multiethnic case control study of African-American, Caucasian, Japanese and 
Chinese men, intake of cruciferous vegetables was inversely related to prostate 
cancer, particularly in advanced cases (P for trend = 0.006), with consistent findings 
across ethnic groups (Kolonel et al., 2000). More recently, Men’s Eating and Living 
(MEAL) study, a promising large scale randomized clinical trial, began assessing 
how dietary modification through increased cruciferous vegetable intake affects men 
with early stage localized cancer (Parsons et al., 2014). 
However, the biochemical relationships between tumor-host interactions with 
cruciferous vegetable-derived bioactive compounds must be fully understood if 
nutrition intervention is to offer cancer preventive or therapeutic benefits.  
Influence of Diet on Chronic Disease 
The role of diet in the prevention, manifestation, progression, and premature 
mortality in association with chronic diseases such as cancer has been well 
established. In an early review by Doll et al, nutritional factors were suspected to be 
one of the leading factors in cancer onset and mortality (Richard Doll et al., 1966; R. 
Doll & Peto, 1981). Surprisingly, 30- 35% of all cancer-related deaths (500,000 at 
that time) were related to dietary factors (Willett, 2000). Scientists have continued to 
study the relationship between diet and health since this foundational study 48 years 
ago. 
Both retrospective and prospective epidemiological studies have found dietary 
quality and lifestyle factors as the main determinants of chronic diseases (Ford, 
Jensen, Hartman, Wray, & Smiciklas-Wright, 2013; Fouwels, Bredie, Wollersheim, 
& Schippers, 2009; E. Liu et al., 2009; Samieri et al., 2013; Van Duyn & Pivonka, 
2000). Findings from a review written by Ford et al. indicated a dietary component 
associated with increased burden of chronic diseases on aging Americans. Of the 
articles reviewed in this article, delayed mortality was associated with individuals that 
adhered to diets that were composed of a variety of wholesome fruits, vegetables, 
whole grains, and other healthful choices (Ford et al., 2013). Moreover, the protective 
role for vegetables in the prevention of coronary heart disease, stroke, diverticulosis, 




Health Benefits of Cruciferous Vegetables 
Benefits associated with healthful eating include decreased risk of chronic 
diseases, reduced overweight and obesity status, and diminished micronutrient 
deficiencies. Improvement of these three overlapping factors alone could significantly 
improve the health of Americans.  
These conditions are heavily influenced by genetic variability and diet 
management. Genetic variability also plays an integral role in disease predisposition 
and manifestation (Brigelius-Flohé, 2006; Stearns; Weiss, 1993). Combining dietary 
and lifestyle factors with genetic variation complicates the identification and 
applicability of discrete roles of risk factors on disease development. However, an 
underlying conclusion from these studies is that nutrition plays a crucial role in 
disease manifestation and progression.  
Poor nutrition and diet management can lead to increased susceptibility of 
disease. In terms of chronic diseases, cancer incidence and mortality are affected by 
an individual’s environment (regional differences), food patterns and related 
behaviors, as well as medical conditions (International Agency for Research on 
Cancer. & International Association of Cancer Registries., 2010). Decreased rates of 
disease incidences, morbidity, and mortality can be achieved through an increased 
understanding of nutritional genomics and timely and effective dietary intervention. 
In this dissertation, I will explore how one possible diet, a diet rich in 
cruciferous vegetables, can be used successfully to prevent chronic diseases such as 
prostate cancer.  
Cruciferous vegetables, members of the Cruciferae (Brassicaceae) family, are 
often characterized as having four equal-sized petals in the shape of a cross.  
Cruciferous vegetables include broccoli, Brussels sprouts, cauliflower, collard greens, 
watercress, wasabi, horseradish, bok choy, and kale. Primary characteristics of the 
cruciferous vegetables are their dense distribution of fiber, carotenoids, vitamins A, 
C, E, folate, and minerals. Moreover, cruciferous vegetables are a rich source of 




Diets rich in cruciferous vegetables play an important role in the management 
of chronic diseases (D. Li, 2014). The impact of cruciferous vegetable intake on 
cardiovascular disease, stroke, diverticulitis, and cancer are reviewed below. 
Protection against Cardiovascular Disease 
Diagnosed, unmanaged cardiovascular diseases (CVD) are one of the leading 
causes of death in the United States. Of these diseases, coronary heart disease is one 
of the most common and serious forms of cardiovascular disease. There has been a 
decline in the number of cardiovascular disease-related deaths. Extenuating 
circumstances such as overweight and obesity prevalence in adults and children are 
aggravating the incidence and invasiveness of these disorders.  
Epidemiological evidence supports the protective role of dark green vegetable 
intake on coronary heart disease (Joshipura et al., 2009; S. Tanaka et al., 2013; X. 
Zhang et al., 2011) as well as reductions in mortality rates among individuals 
consuming daily servings of vegetables (Park et al., 2009). Moreover, decreased 
prevalence of myocardial infarctions and angina pectoris has been associated with 
high intake of raw, leafy, green vegetables and juice (Crowe et al., 2011; Shenoy et 
al., 2010). Diets consisting mostly of vegetables, grains, beans, fruits, and occasional 
dairy in the absence of animal products, in combination with lifestyle changes can 
reverse heart disease without need for medication (Wofford, Greenlund, Croft, & 
Labarthe, 2007).  
Vegetables contain a variety of components that can be attributed to these 
health benefits. Soluble fiber, for example, composing the outer skin and inner pulp, 
has contributed to lowering homocysteine, a known risk factor and biochemical 
parameter commonly used in the assessment of cardiovascular disease (Eilat-Adar, 
Sinai, Yosefy, & Henkin, 2013; Threapleton et al., 2013; W. Xiao et al., 2014). 
Moreover, soluble fiber in vegetables may help to control serum cholesterol levels, 




Protection against Stroke and Diverticulitis 
Stroke and diverticulitis are among other chronic diseases that affect millions 
of individuals each year. Stroke is the 4th leading cause of death in the U.S. In 2010, 
this disease claimed approximately 39.1/ 100,000 lives and nearly 800,000 people 
suffer from stoke each year (Go et al., 2014; Go et al., 2013). Vegetable consumption 
may reduce the risk of stroke. Studies conducted by Joshipura et al and Larsson et al 
have correlated a high vegetable intake with a 19% decrease in ischemic stroke and 
lower mortality rate (Joshipura et al., 1999; Larsson, Virtamo, & Wolk, 2013). In a 
review by Ness and Powles, findings from 3 ecological, 1 case-control, and 4 cohort 
studies revealed a protective effect of fruits and vegetables to be stronger against 
stroke than against coronary heart disease (Ness & Powles, 1997). Moreover, another 
prospective study revealed a 30% reduction in ischemic stroke among men and 
women who consume 6 daily servings of fruits and vegetables, particularly green, 
leafy cruciferous vegetables and citrus fruits (Joshipura et al., 1999; Joshipura et al., 
2009; Ness & Powles, 1997). The beneficial effects mentioned in these studies can be 
attributed to the soluble fiber and complex matrix of bioactive compounds found in 
cruciferous vegetables. Not only do vegetables potentially prevent strokes, but they 
also have been shown to deter diverticulitis. 
Diverticulitis is a chronic disease that primarily affects the inner lining of the 
colon and is characterized with acute and chronic inflammatory states. One cause of 
diverticulitis is low dietary intake of vegetables, which are specifically noted for their 
fiber content (Marlett, McBurney, Slavin, & Association, 2002). Diets rich in 
cruciferous vegetables significantly reduce the incidences of this disease (Aldoori & 
Ryan-Harshman, 2002; Korzenik & NDSG, 2008). Moreover, clinical studies has 
found that prostate and colon-rectum are among cancer types associated with patients 
diagnosed with diverticulitis (Stefánsson, Ekbom, Sparén, & Påhlman, 1995).  
Protection against Cancer 
The reduction of risk factors associated with the development of certain 
cancers has provided additional evidence for the health benefits of vegetable 




American Institute for Cancer Research (AICR) have published numerous reports 
exhibiting an extensive collection of global research that reviews this topic. In a 
World Cancer Research Fund review, strong epidemiological and experimental 
evidence supports the conclusion that diets “high in vegetables and fruits (more than 
400 g/day) could prevent at least 20% of all cancer incidence” (Nutritional Oncology, 
2006). Due to the extensive background on the cancer protective effects of vegetables 
on a host of cancer types, AICR established dietary intake recommendations of 400 to 
800 grams of varied vegetables and fruits per day (World Cancer Research Fund, 
2007).  
Uncovering health benefits associated with the consumption of cruciferous 
vegetables and reduced risk of certain cancers has been of particular interest over the 
past few decades (Farnham, Wilson, Stephenson, & Fahey, 2004). Epidemiological-
based studies have been essential in identifying diet-related issues in health outcomes, 
vegetable intake patterns, and cancer development. In an extensive review conducted 
by Verhoeven et al, 87 case-control studies were analyzed and nearly 67% reported 
an inverse association between cancer risk and the consumption of assorted 
cruciferous vegetables (Verhoeven, Goldbohm, van Poppel, Verhagen, & van den 
Brandt, 1996). Findings from another major review conducted by Hidgon et al, 
epidemiological data revealed the importance of exposure to indoles and 
isothiocyanates within cruciferous vegetables in the reduction of cancer risk. 
Moreover, results from this study indicated the possible influence of genetic variation 
on the cancer protective effects of cruciferous compounds (Higdon, Delage, 
Williams, & Dashwood, 2007). 
Exactly how cruciferous vegetables demonstrate these beneficial effects in a 
variety of cell, animal, and human systems is a critical research area devoted to 
resolving cancer outcomes. Cruciferous vegetables, in both whole and purified, 
isolated forms, have been implicated in regulating a variety of anticarcinogenic 
mechanisms including the modification of chemical compounds by inducting 
enzymatic activity involved in the detoxification of carcinogens and other 
xenobiotics. Cruciferous vegetables are a rich source of glucosinolates, sulfur-




production in cellular and animal studies and inhibit the binding to various cell 
receptors such as the aryl hydrocarbon and androgen receptors in prostate cancer 
(Van Duyn & Pivonka, 2000). 
 
Glucosinolates within Cruciferous Vegetables 
Naturally, human diets are diverse in cruciferous vegetable food sources such 
as Brussels sprouts, collard greens, watercress, and bok choy. Glucosinolates (GLS) 
are secondary plant metabolites found in cruciferous vegetables. Glucosinolates, over 
100+, have been identified and classified into three main groups based on their side 
chain configuration: aliphatic with alkyl or alkenyl group such as sinigrin, progoitrin; 
aromatic with benzyl group such as gluconasturtiin; and heterocyclic with indolyl 
group such as glucobrassicin, neoglucobrassicin. The structural diversity of 
glucosinolates is due to substituted side-chain configurations.  
The total content of glucosinolates as well as their relative abundance not only 
varies by vegetable type but can also vary by vegetable species. Glucosinolate content 
for Chinese cabbage may yield 20 mg/100 g fresh weight versus watercress, which 
may yield 389 mg/100 g fresh weight (McNaughton & Marks, 2003). Glucobrassicin, 
a type of glucosinolate, can account for 8-12% of total glucosinolates in broccoli and 
other dark green vegetable varieties (Fahey, Zhang, & Talalay, 1997; Farnham et al., 
2004; Galletti et al., 2015; Kushad et al., 1999). Therefore, in addition to variety, 
growing conditions and preparation techniques may greatly influence the 
glucosinolate content variability (Fahey et al., 1997; Freeland-Graves & Nitzke, 
2013; Kushad et al., 1999). These are among a myriad of factors complicating the 
development of dietary recommendations for nonessential bioactive constituents 
(Gaine et al., 2013). Nonetheless, estimated intake of glucosinolates was estimated to 
be between 12-16 mg person/day (Fenwick & Heany, 1983; Getahun & Chung, 
1999). The biologically active byproducts of glucosinolates are studied for their role 
in cancer prevention (Cirignano & Morgan, 2014; Fahey et al., 2012; Royston & 




Chemical and Physical Properties of Glucosinolates 
The structures of glucosinolates are diverse. However, the general structure of 
a glucosinolate consists of a β-D-thioglucose group, a sulphonated oxime moiety, and 
a variable side-chain derived from an amino acid. Examples of these amino acids 
include methionine for aliphatic glucosinolates, tryptophan for indole glucosinolates, 
phenylalanine for aromatic glucosinolates, and other branched chain amino acids such 
as isoleucine, alanine, valine, leucine) (Fahey, Zalcmann, & Talalay, 2001). There are 
4 general categories of glucosinolates: 7 glucosinolates are derived directly from the 
amino acid side chains mentioned above. Other glucosinolates are synthesized from 
general ways, which include 1) chain-elongated forms of the amino acids, methionine 
and phenylalanine; 2) modified side chain structures after amino acid elongation and 
glucosinolate synthesis; and 3) complex side chains (such as o-(a -L -
rhamnopylransoyloxy)-benzyl glucosinolate) (Mithen, Dekker, Verkerk, Rabot, & 
Johnson, 2000). 
These phytochemicals are constitutively found in plant sources. Given their 
structure, glucosinolates may remain chemically stable within the cytoplasm until 
hydrolyzed by myrosinase upon tissue disruption. Upon hydrolysis, glucosinolates 
yield equimolar quantities of glucose, aglycone and sulphate molecules. The 
instability of the aglycones causes the compounds to be further metabolized to yield 
thiocyanates, nitriles and isothiocyanates. The structure of the side chain and reaction 
conditions will determine its final structure (Fahey et al., 2001; Mithen et al., 2000).  
Bioactive Components within Cruciferous Vegetables 
Indoles and isothiocyanates have been identified as active components present 
in Brassica vegetables with protective effects against prostate cancer (Beecher, 1994; 
Talalay & Fahey, 2001; Y. Zhang & Talalay, 1994). Glucosinolates are hydrolytically 
cleaved by myrosinase, an endogenous plant enzyme that is activated upon 
mechanical injury and yields bioactive components such as indoles and 
isothiocyanates. Interestingly, if ingested glucosinolates bypass myrosinase 
conversion, they have been shown to undergo conversion to indoles and 




been shown to exhibit myrosinase activity (Fahey et al., 2012; Getahun & Chung, 
1999; Kensler et al., 2005; Shapiro, Fahey, Wade, Stephenson, & Talalay, 1998). The 
bioactive phytochemicals released from glucosinolates have gained a significant 
amount of attention for their anti-cancer activity. Controlled experimentation with 
glucosinolate derivatives, such as indole-3-carbinol (I3C) and phenethyl 
isothiocyanate (PEITC) have helped to characterize inhibitory and cytotoxic activity 
in prostate cancer cells and animal model systems and have provided a mechanistic 
explanation for how crucifers are causative in lowering cancer risk. 
 
Figure	  1	  Chemical	  Structures	  of	  indole-­‐3-­‐carbinol	  and	  phenethyl	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Indole-3-carbinol, a Glucobrassicin-derived bioactive compound 
Indole-3-carbinol (I3C) is a diet-derived bioactive compound generated by the 
hydrolysis of glucobrassicin from cruciferous vegetables (Fig.1, adapted from 
(Broadbent & Broadbent, 1998a)) . Glucobrassicin yields unstable intermediate 
aglycone products when combined with myrosinase, a plant defense enzyme activated 
upon mechanical injury such as chewing. I3C is a major indolic compound that is 
vigorously studied for its chemopreventive properties. Inhibitory effects of I3C lies 
within its ability to yield aromatic hydrocarbon byproducts such as 3 -, 3’ -
diindolylmethane (DIM) under acidic aqueous conditions (Bjeldanes, Kim, Grose, 
Bartholomew, & Bradfield, 1991).  Formation of these metabolites is dependent upon 
environmental pH. Typically, DIM’s highest formation levels/ yields occur between a 
pH of 4 to 5, similar to the pH range of mammalian stomach acid.  
Furthermore, in vitro studies have shown that I3C does not induce 
cytotoxicity, is not mutagenic, and can be tolerated in doses up to 1,200 mg/d when 
consumed in controlled human subject testing (Meng et al., 2000; Reed et al., 2006; 
Reed et al., 2005; N. Takahashi, Dashwood, Bjeldanes, Williams, & Bailey, 1995; T. 




recurrence following prostate cancer surgery have also been assessed. Participants 
were given a placebo, 2 servings of Brassica vegetables, or an I3C supplement for 6 
months, however, results from this study have not been published (Clinical Trial ID: 
NCT00607932) Part of I3C’s benefits lies within its ability to induce phase 1 and 2 
drug metabolizing gene expression, which enhances modification and excretion of 
harmful substances. Moreover, I3C has been noted for its antiangiogenic effects on 
tumor cells lines and its elicited effects on immune response (Tsai, Liu, & Chen, 
2010; T. T. Wang et al., 2012). 
 Amounts of I3C found in diets vary due to its chemical instability within 
individual vegetables. However, I3C has been found in concentrations of 
approximately 50 µg (339.7 µmol)/g dried vegetable diet (Bradfield & Bjeldanes, 
1987). Estimated intake of I3C in the U.S. may be less than 2.64 mg/day based on an 
estimated vegetable intake of 2 ounces per day (Broadbent & Broadbent, 1998a).  
Phenethyl isothiocyanate, a Gluconasturtiin-derived bioactive compound 
Phenethyl isothiocyanate (PEITC) is another example of a diet-derived 
bioactive compound derived from the hydrolysis of gluconasturtiin in Brassica 
vegetables (Fig. 1, adapted from (Moon, Brazeau, & Morris, 2011)). PEITC and its 
derivatives are also extensively studied for their chemopreventive properties. 
Depending on the reactive conditions, phenethyl isothiocyanate is yielded from 
glucosinolates via the mercapturic pathway. PEITC-NAC and several other thiol 
conjugates of isothiocyanates have been reported as primary metabolites of PEITC. 
Amounts of PEITC found in the diet may vary based on vegetable composition. 
Watercress, for example, has been shown to yield approximately 12 mg PEITC/57 g 
wet weight (F. L. Chung, Morse, Eklind, & Lewis, 1992). A clinical trial in progress 
is assessing the effects of watercress juice (55 g watercress) on oral cancer of patients 
considered heavy smokers (ClinicalTrial.gov ID: NCT01790204). 
Biological activities of Glucosinolate Compounds, I3C and PEITC 
The potent chemopreventive activity of isothiocyanates has been 




models include hepatocarcinoma, mammary gland and other breast cancer cell lines, 
esophageal, pancreatic, gastrointestinal, and urinary and bladder of mice, rats, and 
other rodents and prostate, breast, colon cancer in humans (F. L. Chung et al., 1992; 
Hecht, 1995; Khor, Cheung, Prawan, Reddy, & Kong, 2008; Y. S. Kim & Milner, 
2005; Moy et al., 2008). 
Moreover, I3C and PEITC have attenuated growth in various cell models 
including the classic LNCaP, PC3, and DU145 lines. Moreover, these compounds are 
unique in their ability to differentially regulate cell growth. I3C, for example, has 
been shown to act as a regulator of the androgen responsive pathway. On the other 
hand, PEITC has been shown to inhibit growth independent of the androgen pathway 
through attenuation of angiogenesis and other biological pathways (Firestone & 
Sundar, 2009).  
 Initially, isothiocyanates’ specific modes of action were thought to be through 
the regulation of Phase 1 and Phase 2 detoxification enzymes within carcinogenesis 
models. Findings from Chiao et al indicated that isothiocyanates and their metabolites 
mediate other functions including growth inhibition and apoptosis induction in 
prostate cancer cells (Chiao et al., 2000; Shapiro et al., 1998). Results from this study 
indicated the effectiveness of isothiocyanates at the post-initiation and progression 
stages of carcinogenesis (Moy et al., 2008; Rose, Faulkner, Williamson, & Mithen, 
2000).  
In addition to genetic alterations, the regulation of epigenetic mechanisms is 
an important factor contributing to the development and progression of prostate 
cancer. Epigenetic regulation is considered heritable changes (DNA hypermethylation 
and hypomethylation, and histone modifications) in gene expression that occur 
without changes in DNA sequence (W Watson, M Beaver, E Williams, H Dashwood, 
& Ho, 2013).  
Anti-proliferation 
I3C and PEITC have been well studied for their anticarcinogenic properties in 
in vitro cell model experiments and in vivo animal and human subject studies. 




protective properties as evidenced by inhibited tumor growth. Findings have shown 
that I3C and PEITC may also enhance cancer progression if exposed following 
initiation (D. J. Kim et al., 1997). However, the majority of reports overwhelmingly 
supports the anticarcinogenic effects of these compounds and supports their usage as 
candidate chemopreventive agents.  
I3C plays a critical role in regulating prostate cancer cell growth. Previous 
studies have shown that I3C can inhibit cell growth of androgen-dependent and –
independent cell lines including LNCaP, DU145, as well as PC-3, a poorly 
differentiated PCa cell line via the induction of G1 cell arrest and apoptosis following 
exposure to 30 to 100 µM of I3C (Chinni, Li, Upadhyay, Koppolu, & Sarkar, 2001; 
Chinni & Sarkar, 2002; Nachshon-Kedmi, Yannai, Haj, & Fares, 2003; Yeh et al., 
1999). Proposed mechanisms for I3C growth inhibition in androgen independent cell 
lines may be through the inactivation of AKT and NF-κΒ (Aggarwal & Ichikawa, 
2005; Jin et al., 2008; J. Zhang, Hsu B A, Kinseth B A, Bjeldanes, & Firestone, 
2003). In a study conducted by Souli et al, I3C (20 mg/kg body weight) was 
administered before and after transplanting TRAMP-C2 prostate cancer cells, which 
inhibited xenograft tumor growth by 78%, decreased proliferation (3 folds lower Ki67 
staining), and promoted apoptosis (caspase 3 staining) as well as decreased 
angiogenesis by modulating microvessel density (CD 31 endothelial marker). These 
results were also correlated with the author’s in vitro I3C treatment with the TRAMP-
C2 cell line (Souli, Machluf, Morgenstern, Sabo, & Yannai, 2008).   
PEITC has been shown to inhibit growth of locally isolated and metastatic 
prostate cancer cell growth. Proposed mechanisms for PEITC-induced apoptosis in 
advanced prostate cancer may be a result of caspase-3-dependent mechanisms as well 
as through the inhibition cell survival that is mediated by the activation of 
extracellular signal-regulated kinases (ERK 1 and -2) or phosphorylation of IKK-α 
and IKK-β (Hudson et al., 2012; Powolny et al., 2011; D. Xiao et al., 2006).  
Chemopreventive effects of PEITC have also been studied in animal models. 
Rodents fed low concentrations of PEITC (≤ 5 µM), had significantly lower tumor 
growth within weeks of cancer initiation (F. L. Chung et al., 1992; Powolny et al., 




treatment with 3 µmol PEITC/g diet using a more advanced prostate cancer xenograft 
model was not associated with a decrease in cell proliferation, apoptosis induction or 
select neogenesis biomarkers. Instead, the proposed pathways for the 26.48% 
decrease in tumor burden may have been due to the induction of autophagy. 
Conclusions from these studies highlight the complexity of tumor modulation and 
importance of examining physiologically-relevant dosing in various animal and cell 
models (Hudson et al., 2012).  
Anti-inflammation 
Glucosinolates are ideal inflammatory regulators due to their low side effects 
at physiologically relevant doses. I3C’s and PEITC’s anti-inflammatory effects have 
been demonstrated through the inhibition of cytokine production. Moreover, dietary 
supplementation with I3C and PEITC inhibited in vivo tumor growth through the 
suppression of anti-inflammatory biomarkers such as CD31 and VEGF (Hsu et al., 
2005; Hudson et al., 2012; Souli et al., 2008). I3C (50 µM) and PEITC (5 µM) have 
been showed to moderately inhibit the production and release of cytokines such as IL-
10 (anti-inflammatory) and TNF-α (proinflammatory) in macrophages under in vitro 
conditions. These results suggest that inhibition of these cytokines may rely on 
suppression of gene expression via NF-κΒ pathway (Aggarwal & Ichikawa, 2005; 
Tsai et al., 2010).  
I3C and PEITC may differentially regulate cytokine production within 
prostate tumor cells. I3C has been shown to regulate monocyte/macrophage attraction 
in LNCaP, human prostate cancer cells. In a study conducted by Kim et al, I3C and 
its metabolites significantly inhibited promotional effects of DHT on CCL2 
expression and monocyte migration (E. K. Kim, Kim, Milner, & Wang, 2013). 
PEITC has been shown to retard tumor growth independently of androgen responsive 
pathways. One mechanism lies in PEITC’s ability to regulate inflammation within the 
tumor microenvironment. PEITC has also been studied for its effects on 
proinflammatory cytokines in macrophages (Tsai et al., 2010). Hudson et al, further 
demonstrated the ability of low dose PEITC to obstruct angiogenic properties by 




results from this study indicated that PEITC had little effect on cell proliferation, cell 
cycle, and androgen-dependent pathways. More importantly, transcriptomic analysis 
of this mouse population treated with 3 µmol/g diet PEITC revealed significant 
changes along other pathways such as inflammatory status that may affect tumor 
growth (R. W. Li, Li, & Wang, 2013). 
Due to the complexity of cytokine interactions, which may act synergistically 
or additively, results may differ within animal and human models and warrant further 
investigation (Gannon, Malone, & Napolitano, 2001; Pruett, Fan, Zheng, & Schwab, 
2005). 
Xenobiotic Clearance 
Carcinogenic inhibitory properties of I3C and PEITC has been demonstrated 
through the alteration of xenobiotic metabolism within carcinogenic and xenograft 
models.  
I3C and its metabolites have been shown to modulate xenobiotic metabolism 
when administered through the diet. The ability of I3C to induce CYP1 family, such 
as CYP1A1, and regulate ligand-activated aryl hydrocarbon receptor (AhR) has been 
extensively studied in human cell lines and animal models. Following ligand binding, 
the AhR translocates into the nucleus and forms a heterodimer with ARNT, a member 
of basic helix-loop-helix/Per-ARNT-Sim family. The heterodimer then binds to 
xenobiotic response elements (XREs) in the promoter and enhancer regions of targets 
genes to regulate their transcription (Hestermann & Brown, 2003). The expression of 
phase 1 enzymes, which may activate procarcinogens, is responsible for modifying 
the structure and functionality of the xenobiotic by adding a polar group (Hestermann 
& Brown, 2003; Yu & Kong, 2007).  
These enzymes are mainly regulated through xenobiotic sensing nuclear 
receptors such as AhR, constitutive andostane receptor (CAR), pregnane-X receptor 
(PXR), and retinoid-x receptor (RXR). Human subfamilies primarily involved in 
xenobiotic metabolism include CYPs 1A, -2C, -2D, -2E, and -3A, with varied but 
overlapping substrate-specificity (Kirchmair et al., 2012). Phase 2 enzymes, including 




dehydrogenase, quinone 1 (NQO1),  are known to be induced by I3C and are 
responsible for facilitating complex excretion processes such as glucoronidation of 
modified xenobiotics (Shertzer & Sainsbury, 1991a). As a result, these enzymes may 
catalyze the conjugation of carcinogens and other substances. Generally, these 
enzymes are transcriptionally controlled by the Nrf2/ARE signaling pathways.  
The signaling pathways regulate the expression of many detoxifying enzymes 
and the ability to inhibit or activate the expression these enzymes are a major target 
for dietary compounds. The chemopreventive effects elicited by these compounds are 
determined by a network composed of known and unknown molecular targets, their 
signaling pathways and its interaction with various xenobiotics, including 
carcinogens, drugs, and other dietary factors (Kensler et al., 2005; Talalay & Fahey, 
2001; Yu & Kong, 2007). Thus, the exact mechanisms underlying the ability of I3C, 
PEITC, or their metabolites to induce Phase 1 and 2 xenobiotic metabolizing enzymes 
via the aryl hydrocarbon receptor are unclear. 
Research Methodology 
Chemoprevention refers to the use of naturally found, bioactive compounds in 
the prevention of prostate cancer, as adapted from (Sporn, 2011). Highly standardized 
analytical, practical, and efficient techniques, such as real-time PCR, Western Blot, 
and ELISA have been promoted as important research methodology for determining 
the efficacy of cruciferous vegetable-derived compounds on prostate cancer and 
inflammation encompassing the tumor microenvironment.  
A variety of methods are employed to assess molecular sensitivities within the 
prostate cancer microenvironment following exposure to cruciferous vegetable-
derived biological compounds. Utilizing cell-based assays have been a common 
practice to probe for bioactivity potential and chemopreventive effects of 
phytochemicals. These assays serve as swift, inexpensive means of analysis prior to 
initiating in vivo studies, which can provide a more physiologically relevant response.  
Under in vitro conditions, growth inhibition, anti-proliferation, and cell 
adhesion assays were used to evaluate changes in cell viability and proliferation, 




mammalian cancer progression. Moreover, cell proliferation and growth assays are 
well established methods used to distinguish effective dosage from no effect levels 
and assess the responses of these concentrated phytochemicals on cell viability. Cell 
adhesion involves a variety of molecular processes such as receptor-ligand binding 
and changes in intracellular pathways. Cell adhesion assays provide insight on the 
changes in a cell and its extracellular adhesion proteins as well as other cellular 
events. The adhesion assay in this study has been commonly used to examine the 
sensitivity of a specific cell line and its substrate in the presence of an inhibitor, 
which in our case, are the candidate phytochemicals. All three assays are analyzed 
using the sulforhodamine B (SRB) method. SRB assay, discussed below, is another 
well-established method used in the quantification of adherent cell lines to an 
immobilized substrate.  
Changes in cancer status are reflected by developmentally programmed gene 
expression patterns. The responsiveness of cell lines with dysregulated genes assist in 
facilitating the evasion of antineoplastic controls, including apoptosis, and cell cycle 
checkpoints. Analytical methods used to assess in vitro as well as in vivo changes 
include SRB method, to quantify changes in cell number, RT-PCR, to quantify 
relative changes in genomic expression levels.  
SRB is a commonly used screening method to measure the loss of cell 
viability. It is often used a first-step assay to determine whether a compound has the 
ability to cause decreased cell proliferation, survival, or cell death at a single 
intracellular end-point before more intensive methods are used. SRB is an anionic 
aminoxanthene dye, which forms an electrostatic complex with basic amino acid 
residues of proteins (Skehan et al., 1990). The uses of this assay are numerous. It is 
commonly employed in a number of high-volume screening applications, is mostly 
known for its sensitive linear response, rapid color development and stable sensitivity 
when read at absorbances between 560 and 580 nm (Skehan et al., 1990).  
Polymerase Chain Reaction (PCR) is an exquisitely sensitive, powerful, and 
central molecular biological method to detect amplified template nucleic acid PCR 
products. The use of real time, Reverse-Transcription Polymerase Chain Reaction 




demonstrated in cell viability assays with a more comprehensive analysis of gene 
expression data yielding information on target regulators of signaling pathways 
involved in cell survival, proliferation, xenobiotic metabolism, and inflammation 
(Provenzano & Mocellin, 2007). The principles and practical uses of RT-PCR have 
been extensively review (Jozefczuk & Adjaye, 2011). 
Techniques utilized in the detection of protein are manifold. For this reason, 
the selection of suitable approaches to optimally measure changes in expression 
levels according to the biological question, sample type and other methodical 
requirements is critical. Western blot, enzyme-linked immunoabsorbent assays, and 
immunohistochemistry are well within the most distinguished and desirable practices 
in scientific research and medical diagnosis within clinical disciplines.  
Western blot, developed nearly four decades ago, is a fairly common detection 
method used to identify the nature or epitope of a protein. Detection of a desired 
protein occurs following gel electrophoresis separation, which spans transferred 
proteins across a nitrocellulose membrane prior to being exposed to antibodies 
against proteins of a desired molecular weight. In our study, the proteins of interested 
were revealed via infrared fluorescent detection, a relatively new detection method. 
Immunoassays measure antibodies with varying degrees of sensitivity. 
Enzyme-linked immunoabsorbent assay (ELISA) may detect less than 0.001 ng/mL. 
This assay has been used in a variety of molecular processes to sensitively, quantitate 
levels of protein by an approach termed “sandwich enzyme immunoassay”. In our 
studies, this technique was used with sequential mouse monoclonal antibodies. When 
the immunocomplexes are assayed with an appropriate substrate such as peroxidase, 
the levels of the product can be quantitated colorimetrically and a directly 
proportional to the degree of protein product induced or reduced by the test 
compounds. ELISA is a highly sought-after method because of its lower cost, safety, 
speed, and simplicity in comparison to radioimmunoassays. 
Diagnostic immunohistochemistry (IHC) has been a rapidly evolving field. 
However, foundational principles of IHC still operate under the notion that the 
distribution of antigens of interest can be detected in tissues often times using mono- 




and ELISA, IHC enables pathologists and other researchers to visually assess and 
grade changes of a protein of interest within a particular cell or tissue (Duraiyan, 
Govindarajan, Kaliyappan, & Palanisamy, 2012). Thereby deeming this practice a 
valuable, gold standard tool in the diagnosis of cancers. IHC plays a fundamental role 
in the gross assessment of tissue functionality or changes in up- or down-regulation of 
specific tumor antigens (E. Rubin & Reisner, 2014). Spectroscopy such as light 
microscopy frequently serves to identify the antigen, which occurs when the substrate 
is degraded by immunoperoxidase to yield a colored insoluble substrate at the 
location of the antibody-antigen complex.  
Staining methods provide immunohistochemistry with a high degree of 
functionality. Hematoxylin and Eosin (H & E) staining is a widely used, principle 
stain in histology and is considered a gold standard diagnostic tool (Bancroft & 
Gamble, 2008). Among a variety of practices, this stain is usually involved in the 
examination of a biopsy to detect suspected cancer (R. Rubin, Strayer, Rubin, & 
McDonald, 2008). Since most cells are transparent, this technique has been used to 
distinguish cell constituents by staining basic components and counterstaining acidic 
components based on their affinity for eosin and hematoxylin dyes (Bancroft & 
Gamble, 2008). Eosin is an acidic dye used to stain basic or acidophilic components 
such as the cytoplasm a red or pink color. Hematoxylin is a basic dye, which stains 
acidic or basophilic components such as DNA: heterochromatin and nucleolus within 
the nucleus and parts of the cytoplasm that contains RNA: ribosomes, and rough 
endoplasmic reticulum, a violet or blue color. Digital light microscopy is considered 
an easy, cost-effective, and efficient method to conduct manual histopathological 
analysis (Bancroft & Gamble, 2008). 
KI-67 staining is a diagnostic tool routinely used in the determination of 
cellular proliferation and in conjunction with other laboratory methods. Assessing for 
changes in growth fraction is important when measuring effectiveness of a treatment 
compound used to recede cancer progression. Overexpression of KI-67 is associated 
with a greater risk of adverse outcomes in prostate cancer (Pollack et al., 2004). As 
with other IHC methods, KI-67 usage extends beyond cancer detection and can be 




included KI67’s reactivity in the organization’s grading system for assessment of the 
gastrointestinal tract (Klöppel, Perren, & Heitz, 2004). KI67 staining is considered a 
superior proliferative marker to PCNA in the colon (Holt, Moss, Kapetanakis, 
Petrotos, & Wang, 1997). In such cases, over expression of KI67 is also associated 
with decreased survival in human and animals (J. Kim et al., 2015; Nishimukai et al., 
2014).  
Evasion of apoptosis is another hallmark of cancer progression. Terminal 
deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labeling (TUNEL) is a 
commonly used assay to detect DNA fragmentation in apoptotic cells (Botelho et al., 
2014; Z. Wang, Yang, Jacob, Aziz, & Wang, 2015). The terminal deoxynucleotidyl 
transferase (TdT) adds dNTPs to the 3’ end of DNA from endonuclease cleavage 
products in the absence of a template. Initially, TUNEL signaling is weak, however, 
within an hour following binding to a strong uniform labeling, intensity increases 
proportionate to nicks in the DNA (Saraste, 1999). Thus, this very sensitive assay can 
quantitate DNA damage from a single to hundreds of cells, including those within the 
gastrointestinal tract (Akpek et al., 2003; C. Gao & Wang, 2009). False positives 
within the assays indicate necrotic cells or cells undergoing DNA repair and gene 
transcription. 
Despite the revolutionized management of this disease from the development 
of biomarkers for prostate cancer screening and detection, the exact mechanisms of 
indole-3-carbinol and phenethyl isothiocyanate on human prostate cancer growth 
inhibition remains elusive. Further validation of existing biomarkers as well as the 
discovery of new markers to identify men at-risk or currently with undiagnosed 
aggressive forms of prostate cancer is necessary.  
 
Summary 
Overall diet quality heavily influences chronic disease development. Diets 
rich in cruciferous vegetables have an essential role in improving health outcomes by 
lessening the manifestation and progression of disease. Bioactive compounds from 




due to their accessibility, bioavailability, and seemingly low side effects. In prostate 
cancer, PEITC and I3C may modulate tumor growth and its surrounding 
environment. Because of their perceived safety and health benefits, increased interest 
has been placed on the use of natural products to prevent or minimize chronic disease 
outcomes. PEITC and I3C have the potential to reduce the incidence of prostate 
cancer and associated poor outcomes by decreasing biological dysfunction and thus, 
minimizing clinical manifestation and advancement. However, the regulatory 
mechanisms in which these compounds elicit these beneficial responses are elusive 
and merit further investigation. 
This dissertation addresses this issue by characterizing deregulated pathways 






Chapter 2: Inhibition of LNCaP, Human Prostate Carcinoma, 
Xenograft Tumor Growth by Dietary Administration of 
Phenethyl Isothiocyanate is associated with Inhibition of 
Macrophage Infiltration and Insulin-like Growth Factor-1 
Pathway 
Abstract 
Phenethyl isothiocyanate (PEITC), a bioactive constituent of cruciferous 
vegetables, is known for its risk-reducing effects against cardiovascular diseases, 
cancer, and secondary contributors such as chronic inflammation. However, its 
mechanism(s) in regulating tumor growth remains unclear. In the present study, 
chemopreventive activity of 5 µmol PEITC/g diet was examined in immune-deficient 
BALB/C nu/nu male mice (5 to 7 weeks old), inoculated with androgen-dependent 
human prostate cancer cell line. Mice were found to be differentially responsive to 5 
µmoles PEITC/g diet and alterations in gene expression were assessed in tumor 
samples.  Tissue analysis revealed a 41.6% decrease in tumor burden, as compared to 
control group, with no observable toxic effects. Consistent with previous in vivo 
findings, PEITC had minimal effects on prostate-specific antigen (PSA), an 
androgen-responsive gene in tumors. Significant reduction of KI67 (11.4%), a marker 
of cell proliferation, was observed in the PEITC treatment group. Moreover, reduced 
expression of EGF-like module containing, mucin-like, hormone receptor-like 
sequence 1 (Emr1 or F4/80) (-38.8%), a macrophage marker was observed.  A 49% 
increase in insulin-like growth factor binding protein 3 (IGFBP3) expression, 
responsible for forming a complex with insulin-like growth factor (IGF) (a prostate 
cancer-associated proliferative hormone), was also significantly altered in tumors of 
mice supplemented with a 5 µmol PEITC/g diet. In summary, dietary administration 
of PEITC in this xenograft model assuaged prostate cancer progression by reducing 
proliferation, macrophage infiltration, and inhibiting IGF-1-mediated pathways.  
Introduction 
Prostate cancer is the most commonly diagnosed non-skin cancer in U.S. men. 
In 2014, there were an estimated 233,000 new cases and 29,480 deaths from prostate 
cancer (DeSantis et al., 2014). While prostate cancer is most frequently diagnosed in 
men 65 years or older, the process of carcinogenesis often takes 10 to 30 years to 
develop from initiated cells to malignant cancer (Howlader, Mariotto, Woloshin, & 
Schwartz, 2014). The presence of prostatic intraepithelial neoplasia and proliferative 
inflammatory atrophy, precursors of prostate cancer, further complicate matters by 
contributing to the long latency period of 10 or more years before invasive 




Delays in neoplastic development and tumor incidence may be achieved through 
pharmacological, hormonal, or nutritional intervention. Early onset prostate cancer 
comes with a higher risk of mortality; therefore cancer prevention and early detection 
are critical (Karchner, Powell, & Hahn, 1999; Kent et al., 2014). In addition, there is 
currently no effective treatment for advanced prostate cancer, which illustrates a need 
to identify and utilize cancer preventive strategies. Recently, published work has 
alluded to the consumption of cruciferous vegetables to have a significant impact on 
prostate cancer eradication (Chan, Van Blarigan, & Kenfield, 2014; W. W. Zhang, 
Feng, & Narod, 2014). As a result, dozen of classes of natural and synthetic 
chemotherapeutic agents are undergoing clinical evaluation to assess their ability in 
reducing the incidence, morbidity, and mortality of the disease. Phenethyl 
isothiocyanate, as one of these agents, holds promise for the prevention of clinically 
aggressive prostate cancer.  
Phenethyl isothiocyanate (PEITC) is a well-documented isothiocyanate, 
derived from the hydrolysis of gluconasturtiin, a glucosinolate commonly found in 
cruciferous vegetables (P. Gupta, Wright, Kim, & Srivastava, 2014; Minarini et al., 
2014). PEITC is generally regarded as safe and has displayed non-toxic effects in 
both animal and human studies when administered in micromole dosages. Moreover, 
the effects of isothiocyanates (ITCs) have been shown to display tumor-specific 
effects. In a recent study conducted by Clarke et al., ITCs selectively induced 
apoptosis and cell cycle arrest in benign hyperplasia, LNCaP and PC3, which are 
androgen-dependent and androgen-independent cell lines, respectively. But did not 
affect PrEC, which is a primary, normal prostate epithelial cell line (Clarke, Hsu, Yu, 
Dashwood, & Ho, 2011). Recent preclinical and clinical studies report enhanced 
tumor resistance within various cancer types following treatment with PEITC (P. 
Gupta et al., 2014). Moreover, PEITC has been shown to mitigate post-initiation 
events leading to the progression of prostate cancer. Proposed mechanisms suggest 
PEITC and its metabolites target the induction of multiple pathways related to 
autophagy, apoptosis, and reduction of angiogenesis, proliferation as well as cell 
attachment in androgen-dependent and independent cell lines. Covalent binding of 




how ITCs start intracellular signaling leading to tumor inhibition is not clearly 
understood. Thus, this research plays significant roles in examining the reduction of 
growth stimulation and sustained survival of prostate tumor cells.  
Stimulated proliferation and enhanced probability of malignant transformation 
of epithelial cells has been attributed to reduced integrin expression, insulin-like 
growth factors (IGFs) and its counterparts. Low integrin gene expression may 
mediate ECM disruption and hinder cell attachment. Studies indicate that insulin-like 
growth factor binding proteins (IGFBPs) regulate cell survival activity (M. Schwartz, 
2014; M. A. Schwartz, Schaller, & Ginsberg, 1995; Waterston et al., 2002). However, 
the balance between growth factors and receptors within the tumor microenvironment 
influences the presence of high affinity IGFBPs. Prostate cancer has a 
characteristically low expression level of IGFBP3 found in the plasma. Low IGFBP3 
levels may be partly due to prostate specific antigen (PSA), which has been shown to 
reduce IGFBP3 affinity for free IGF (Takada, Ye, & Simon, 2007). This protein 
forms a ternary complex with IGF-I or –II and an acid-labile unit. IGFs within this 
complex are sequestered and unable to interact with IGFBPs or IGF receptors along 
the prostate cancer cell surface. Additionally, IGFBP3 may act independently of IGF 
to inhibit cell growth. In response to cellular stress, IGFBP3 has been shown to 
induce apoptosis (Bonkhoff, Stein, & Remberger, 1993; Fornaro, Manes, & 
Languino, 2001; T. H. Lin et al., 2013; Mizejewski, 1999). The anti-tumorigenic 
effects of IGFBP3 plasma proteins may support its usage as a potential end point 
biomarker for prostate cancer. Recent findings from our lab have shown that IGFBP3 
gene expression is significantly increased following dietary exposure to PEITC in 
advanced human prostate cancer xenograft models (Hudson et al., 2012; R. W. Li et 
al., 2013). The full identification of molecular targets and exact efficacy and 
biological mechanisms of PEITC’s anti-carcinogenic effects in vivo are still being 
established. 
The present study examines the effect of dietary administered PEITC on 
LNCaP, human prostate cancer growth in a nude athymic mouse model. This study 
seeks to answer whether PEITC prevents or inhibits the growth of advanced prostate 




regulation of biomarkers related to proliferation, including the up-regulation of 
IGFBP3 and down-regulation of integrins and inflammatory biomarkers. Results from 
this study intend to shed light on the biological significance and elucidation of 
possible mechanisms affected by dietary administered and biologically achievable 
concentrations of PEITC. 
Materials and Methods 
Cell Adhesion Assay 
LNCaP, prostate carcinoma cells were purchased from the American Type 
Culture Collection (Manassas, VA) and grown in RPMI 1640 media supplemented 
with 100 U/ml penicillin, 100 µg/ml streptomycin, and 10% fetal bovine serum (FBS) 
(Invitrogen, Carlsbad, CA). Cells were incubated at 37oC in the presence of CO2-air 
(5:95, v/v).  
LNCaP cells were trypsinized with 0.25% Trypsin-EDTA solution 
(Invitrogen) then seeded in conditioned media with PEITC (0, .1, 1, 2.5, and 5 
µmol/L media) at a density of 0.625 x 105 cells/well in 24-well plates (Corning Inc., 
Corning, NY, USA). Cell plating efficiency was defined as cells attached to culture 
plate surface and was determined by sulforhodamine B (SRB) assay (Hudson et al., 
2012; Skehan et al., 1990) 
Diet Composition 
During the course of the study, mice were provided powdered AIN-93M diets 
in the absence or presence of purified phenethyl isothiocyanate (5 µmol/g diet). Diets 
were formulated by Research Diets (New Brunswick, NJ) and stored at -20°C until 
treatment initiation. Formulation for control and treatment diets were based upon 
previous experiments that assessed quality and quantity of I3C in rodent diets 





Animals were fed 0 and 5 µmol PEITC/g diet for the duration of this study. 
The selected dosage for this study was based upon previous studies reporting 
beneficial effects of this dosage range in both in vitro and in vivo mouse models, 
without any report of adverse effects. A dose of 5 µmol PEITC/g diet in mice is 
roughly equivalent to a human equivalent dose (HED) of 16.54 mg PEITC/kg body 
weight. Moreover, in a clinical oncology study, administration of PEITC have been 
provided in doses of ~14.4 mg/57 g watercress/day in male and female cancer 
patients (Clinical Trial ID: NCT01790204) (F. L. Chung et al., 1992). Therefore, the 
dose selected for this study assesses the effects of tumorigenesis on PEITC 
concentration similar to amounts consumed in the diet as well as amounts supported 
on a low dose chemopreventive range. Moreover in preclinical tumorigenesis studies, 
mice exhibited cancer protective effects following dietary and orally administered 
concentrations of PEITC exceeding 12 µmol/day, ranges that were 2.5 times higher 
than concentrations used in this study (N. Gao et al., 2011; D. Xiao et al., 2006). 
Thereby, deeming the concentration of 5 µmol PEITC/g diet used in this study, safe, 
cautious, and physiologically relevant dosage. 
Tumor Xenograft Model 
LNCaP, an androgen-dependent human prostate carcinoma cell line were be 
used to model response to dietary administered PEITC (ATCC, Manassas, Virginia). 
Prior to inoculation, LNCaP cultures were grown in RPMI 1640 supplemented with 
10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 µg/ml streptomycin 
purchased from Invitrogen (Carlsbald, CA). Cultures were incubated in an 
atmosphere composed of 5% CO2 at 37°C.  
All experimental protocols were in accordance with the National Institutes of 
Health guidelines and were approved by the USDA Animal Research Advisory 
Committee (BAACUC Protocol No. 12-001). Male athymic nude mice (BALB/c 
nu/nu, 20-22 g, 5-7 weeks old) were purchased from Charles River (Frederick, MD) 
and were individually housed in filter-top cages at the USDA BHNRC animal 




of 22 ± 1°C with a 12 hour rotating day and night cycle. Animals consumed food and 
filtered water ad libitum. Food consumption and body weights were recorded weekly. 
An acclimation period of 1 week prior to treatment feedings enabled mice to adapt to 
control AIN-93M diet and environment. Animals were then randomized into two 
experimental feeding groups- (i) control diet, (ii) control diet with 5 µmol PEITC/g 
diets (n = 10/group). Two weeks following treatment initiation, all mice were 
inoculated via subcutaneous injection into the right and left flanks with LNCaP cell 
suspension. Cell suspension consisted of LNCaP cells at a density of 2 x 106 with 50 
µl of phosphate-buffered saline (PBS) and an equal volume of Matrigel (BD 
Biosciences, Mansfield, MA) (Kleinman & Martin, 2005). Injection sites and tumor 
volume (cm3) were monitored and measured weekly for tumor growth and biological 
efficacy: (cm3) = 0.523* x [length (cm) x width2 (cm2)] (Hudson et al., 2012; 
Tomayko & Reynolds, 1989). Mice remained on their respective diets for 7 weeks 
following inoculation. 
Study Termination 
At the end of the study, mice were euthanized using a CO2 chamber and 
necropsy was immediately performed. Blood was collected, stored in vials coated 
with potassium EDTA solution (15% w/v), and placed on dry ice until plasma 
separation. Plasma was separated via centrifugation at 1500 rpm for 30 min at 4°C. 
Soft tissue including tumor, liver, kidneys, and spleens were collected and 
subdivided. Samples were immediately frozen in liquid nitrogen for protein analysis 
or in RNAlater, an RNA stabilizing agent purchased from AMBION Inc. (Austin, 
Texas). Samples were stored in an -80°C freezer until further analysis. 
in vivo RNA Isolation and Reverse-transcription (RT)-PCR 
For determination of mRNA expression in tumor and liver samples, total RNA 
was isolated and purified using RNeasy (Qiagen Inc., Valencia, CA), according to 
manufacturer’s protocol. StrataScript First Strand complementary DNA Synthesis kit 
from Stratagene (Santa Clara, CA) were used to reverse transcribe complementary 




PCR System using TaqMan® Gene Expression Assay (Carlsbad, CA). Relative 
mRNA levels for analysis of gene expression changes were quantified using ΔCt 
method, a previously described TaqMan real-time RT-PCR method (E. K. Kim et al., 
2013; Yuan, Reed, Chen, & Stewart, 2006). TATA box binding protein (TBP), a 
housekeeping gene, was used to calculate relative gene expression levels in soft tissue 
samples. 
 
Marker genes for pathways related to carcinogenesis are listed in Table 1.  
Table	  1 
Pathway Human Mouse 
Androgen Response PSA/KLK3, NKX3.1  
Proliferation Ki67  
Growth Factor IGFBP3  
Inflammation IL-6 I1-6, Il-1β 
Macrophage  Emr1/ F4/80 
ECM Integrins, FN1  
 
Protein Analysis 
In order to identify post-translational changes of mRNA level gene changes, 
two protein analysis methods were utilized. Immunohistochemistry analysis was used 
to examine gross morphological changes in soft tissue samples. ELISA was utilized 
to analyze circulating inflammatory-related protein (interleukin-6) changes in isolated 
plasma. Assays were performed using a commercial kit according to manufacturer’s 
protocols (eBioscience, San Diego, CA). 
For Western blot analysis, tumor samples from 7 mice in each dietary 
treatment group were used. Western analysis was performed according to the 
manufacturer’s protocol (Life Technologies, Grand Island, NY). Anti-β-actin was 
used as a loading control and LNCaP lysate was used as a positive control. 





The 10 animals used per group give >95% power to detect effects with a 
magnitude of at least 10%. Mean body weights, food consumption, and tumor growth 
was used in the preliminary assessment of treatment groups. All end point assays 
were conducted in triplicate and averaged for group analysis. Means were reported as 
mean ± SEM. One-Way Analysis of Variance (ANOVA) and Bonferroni test were 
conducted to determine the differences among means. Statistical significance was 
declared at p < 0.05 using SPSS for Windows (version rel. 21.0, SPSS Inc., Chicago, 
IL) and GraphPad Prism 5 for Windows (version rel. 5.01, 2009, GraphPad Software, 
Inc., La Jolla, CA). Power calculations were completed using SAS 9.3 (version 
6.1.7601, 2010). 
Results 
Effects of PEITC Intake on Body Weight and Food Consumption 
Phenethyl isothiocyanate is a candidate chemopreventive agent. During the course 
of this study mice exposed to 5 µmol PEITC/g diets were assessed for physical and 
molecular changes at a concentration comparable to an average consumption amount 
of 204.05 mg PEITC/kg BW/day.  
 
 
Figure 2 Body weight and food consumption patterns in athymic mice. Mice were randomized into two groups 
and fed 0 and 5 µmol PEITC/g diet for 9 weeks. Average A) body weights and B) food intake were recorded 
weekly and reported in g. Values are reported as means ± SD. n = 7 animals/control and 8 animals/5 µmol 
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PEITC/g diet treatment groups. (*) represents significant differences between mice fed control and treatment diets 
at p< 0.05. 
Over the course of the treatment, mice were weighed and changes in body weight 
and food consumption were monitored. No significant differences in body weight or 
food consumption were observed in any treatment groups. Relative body weight 
remained constant during the course of treatment despite significant increases in 
tumor weight. Average weight and food consumption within treatment groups slightly 
decreased during the final weeks of treatment, which may be attributed to cancer-
related cachexia in mice. PEITC may induce palatability changes given that the 
structure of the compound may elicit a sour taste.  
Effect of PEITC on Xenograft Tumor Growth 
 
 
Figure 3 Tumor Growth and Formation in Treatment Mice. Tumor growth and formation in PEITC treatment 
mice. LNCaP human prostate cancer cell xenografts was established in athymic nude mice. Tumor volume was 
measured weekly and caluclated in described Materials and Methods section. Mean tumor volume in control and 
treatment mice during 9 week treatment period. Values are reported as means ± SD. n = 7 animals/control and 8 
animals/5 µmol PEITC/g diet treatment groups. (*) represents significant differences between control and 
treatment diets at p < 0.05. 
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Changes in temporal tumor growth were assessed in 0 and 5 µmol PEITC/g diet 
treatment groups. During the final weeks (7 and 8) of treatment, tumor growth was 
41.6% lower in mice fed 5 µmol PEITC/g diet. In our xenograft model, we found 
tumor growth to be inhibited within weeks following inoculation. Therefore, we 
further characterized the tumor and surrounding microenvironment utilizing a 
deductive approach. 
Effect of PEITC on Androgen-responsive, Proliferative, and Inflammatory Pathways 
 
Figure 4 PEITC did not significantly affect androgen responsive genes in LNCaP xenografts. A) PSA/ KLK3 and 
B) NKX3.1 expressions in LNCaP tumor xenograft model. Relative mRNA expression of PSA/ KLK3 and 
NKX3.1 was assessed in LNCaP prostate cell tumor samples from control and PEITC-treated mice as described 
previously in Materials and Methods section. n = 7 animals for control and 8 animals for PEITC treatment groups. 
Results are reported as means ±SE. (*) represents p < 0.05. 
Elevated androgen levels are a known risk factor for prostrate cancer and are 
associated with increased cell proliferation and evasion of apoptosis signals. In a 
previous study from our lab, PEITC significantly inhibited tumor growth without 
significantly altering PSA/ KLK3 on transcription or protein levels (T. T. Wang et al., 
2008). In this study, PSA/ KLK3 and NKX3.1, androgen-responsive genes, were 
chosen as relevant endpoint biomarkers. There were no significant changes in KLK3 












































Figure 5 PEITC reduced tumor cell proliferation but did not significantly affect in vivo inflammatory markers. 
Real-time PCR analysis of mRNA expression of proliferative (KI67) and inflammatory markers (Il-1β and Il-6) in 
control and PEITC-treated LNCaP xenograft model. Real-time PCR was performed as described in Materials and 
Methods section. n = 7 animals for control and 8 animals for PEITC treatment groups. Results are reported as 
means ±SE. (*) represents p < 0.05 
 
Figure 6 PEITC did not significantly affect circulating Il-6 levels. Circulating Il-6 protein levels in plasma of mice 
treated with control and 5 µmol PEITC/g diet was assessed using ELISA as previously described in Materials and 
Methods section. n = 7 animals/treatment group. Results are reported as means ±SE. (*) represents p < 0.05. 
 
Inflammation was assessed for possible reductions following PEITC treatment. 
However, there were no significant changes in relative gene expression of Il-1β or Il-
6 levels (Fig. 5). Although not significant, slight declines were observed in circulating 
















































































KI67 is a proliferation marker due to its presence in the G1, S, and G2 cell cycle 
phases and absence in quiescent G0 cells. KI67 gene expression in mice treated with 5 
µmol PEITC/g diet was significantly inhibited by 11.4% following treatment. 
 
Effect of PEITC on Growth Factor Binding and Macrophage Infiltration 
 
Figure 7 PEITC treatment significantly affected IGF pathway and macrophage infiltration. A) IGFBP3 and B) 
F4/80 expressions in LNCaP tumor xenograft model. Relative mRNA expression of IGFBP3 and F4/80 was 
assessed in LNCaP prostate cell tumor samples from control and PEITC-treated mice as described previously in 
Materials and Methods section. n = 7 animals for control and 8 animals for PEITC treatment groups. Results are 
reported as means ±SE. (*) represents p < 0.05. 
Insulin-like growth factor 3 (IGFBP3), insulin-like growth factor 1 binding 
protein 3 was identified as a novel gene up-regulated by PEITC (R. W. Li et al., 
2013). This gene plays a crucial role in the regulation of cell growth. IGFBP3 forms a 
ternary complex with insulin-like growth factor 1 or -2 and insulin-like growth factor 
acid-labile subunit (IGFALS) (Gu et al., 2010; Johansson et al., 2009). However, 
LNCaP, inherently under-expresses IGFBP3 receptors and enables IGF1 to freely 
circulate. As one of the most abundant IGF binding proteins, its effects on intrinsic 
growth regulation have conjured interest as a possible prognostic biomarker. Since 













































interest. We found a significant induction (49%) in IGFBP3 expression following 
treatment with 5 µmol/PEITC (Fig. 7). 
EGF-like module-containing mucin-like hormone receptor-like 1 (EMR1) and 
F4/80, its mouse homologue, is derived from the B cell, myeloid lineage (Xu et al., 
2013). It is a transmembrane protein that is expressed on the cell surface of human 
macrophages. It is commonly used as a mature macrophage infiltration marker in 
mouse and human models (Bucana, Fabra, Sanchez, & Fidler, 1992; Ikehara, Maeda, 
Kimura, Saito, & Ochiai, 2012). In this study, F4/80 gene expression was 
significantly reduced by 38.8% within tumors of mice treated with 5 µmol PEITC/g 
diet. 
Overall, decreased macrophage infiltration and increased IGFBP3 gene 
expression observed in this study suggests that that an inflammatory- suppressed 
tumor environment may contribute to decreased tumor growth in PEITC fed mice. 
Although significant differences in tumors of control and PEITC fed mice could not 
be confirmed on a protein level (Fig. 8). 
 
 
Figure 8 Effects of PEITC treatment on IGFBP3 and F4/80 protein levels. Changes in protein levels were 
assessed in tumor samples of control and PEITC fed mice using Western Blot analysis as described previously in 
















































Effect of PEITC on Cell Adhesion and in vitro Proliferation 
 
 
Figure 9 Effects of PEITC on LNCaP prostate cancer cell proliferation and cell adhesion in vitro. A)72 hr 
proliferation assay. LNCaP cells were plated in 24-well plates and after 24 hr plating period, cells were treated 
with 0, 0.1, 1, 2.5, and 5 µmol PEITC/L media for 72 hours. B) Cell Adhesion assay. LNCaP cells were plated in 
24-well plates and were treated in the presence of 0, 0.1, 1, 2.5, and 5 µmol PEITC/L media for 24 hours. All 
treatment plates were analyzed via SRB method as described in Materials and Method section. n = 4 per treatment 
group. Results are reported as means ±SE. (*) represents p < 0.05. 
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Small but significant reductions in KI67 gene expression in vivo lead to further 
assessment of PEITC on LNCaP growth under in vitro conditions. When treated with 
concentrations greater than 2.5 µmol PEITC/L media, cell growth was significantly 
affected after 72 hour treatment (Fig. 9A). Moreover, cell plating efficiency was also 
assessed in LNCaP cell line. These results correspond with previous lab findings 
(Hudson et al., 2012). Response to PEITC on cell adhesion was assessed in LNCaP 
human prostate cell line. Interestingly, we found that in the presence of PEITC in the 
media led to a significant reduction in LNCaP plating efficiency, which was observed 
at relatively low (2.5 µmol/L) concentrations (Fig.9B).  
 
Figure 10   PEITC significantly affects integrins with LNCaP xenograft. Levels of A) ITGA6, B) ITGB1, and 
C) FN1 mRNA relative to TBP were quantified by RT-PCR as described in Materials and Methods section. n = 7 
animals and 8 animals in control and 5 µmol PEITC treatment groups, respectively. Results are reported as means 
±SE. (*) represents p < 0.05. 
Moreover, we assessed PEITC’s role in altering integrin-mediated cell adhesion 
under in vivo conditions. mRNA expression of integrins A6 and B1 were significantly 
inhibited by 21.9 and 24.8%, respectively, following PEITC treatment (Fig. 10). 
There were no significant changes found in FN1 expression, which is a commonly 
used marker of cell motility (Fig. 10). 
Discussion 
In the current study, we demonstrated that PEITC is capable of inhibiting 































































administration of this compound without negatively affecting food consumption 
patterns and body weight, altered genomic regulation of proliferation pathways within 
the tumor; and significant changes to IGF-1, tumor macrophage infiltration, and cell 
adhesion pathways within the surrounding microenvironment. 
Potential chemopreventive effects of bioactive compounds derived from 
cruciferous vegetables against prostate cancer are well established (Hecht, 1995; 
Moon et al., 2011; Powolny et al., 2011; D. Xiao et al., 2006). But the exact 
regulatory mechanisms of these compounds are not fully known. Physiologically 
relevant exposure of PEITC was administered to these animals in dosage equivalent 
204.05 mg/kg BW/day and the modulations of multiple molecular pathways were 
evaluated. Significant modulation of proliferation, IGF-1, tumor macrophage 
infiltration, and cell adhesion pathways was identified at transcriptional level. Protein 
analysis of F4/80 and IGFBP3 did not reveal any significant changes, which may be 
due to specific targeting of molecular genes that are not expressed post-
transcriptionally (Ozsolak & Milos, 2011). Another possible reason may be due to 
normalization differences in relative mRNA expression and protein analysis, for 
example, in PCR mouse TBP is specifically used as a housekeeping gene to analyze 
F4/80 levels and total protein was used in Western blot analysis. 
Immunohistochemical analysis of tissues stained with F4/80 may provide a more 
accurate account of the presence of macrophages and should be explored in future 
studies.  
Integrins, as important therapeutic targets in prostate cancer, are substantially 
modulated by PEITC. In a recent study conducted by Hudson et al., PEITC 
significantly altered integrin-signaling pathways by reducing the expression of major 
integrins such as ITGA2, ITGA6, and ITGB1 in LNCaP cell line (Hudson et al., 2012). 
Our findings further support PEITC’s ability to regulate integrin-mediated cell 
adhesion through the modulation of ITGA6 and ITGB1 under in vivo conditions. 
These findings have the potential to be of great clinical importance as changes in 
integrin expression have been correlated with decreased cell motility and thus, a less 




The results of our study are particularly interesting when compared to in vitro 
exposure to PEITC on LNCaP cell models. Treatment under similar conditions at a 
lower concentration of PEITC indicated that integrin and IGF pathways were affected 
by PEITC in vivo; our study further supports these findings and may indicate a 
compensatory role under in vivo conditions that requires further investigation. 
Conclusion 
In conclusion, when PEITC is administered in low doses, tumor growth in 
animals was significantly inhibited weeks after inoculation of LNCaP, human 
prostate cancer cells. PEITC displays pluripotent, and potential chemopreventive 
effects within the tumor microenvironment by significantly reducing proliferation, 
inflammation and tumor macrophage infiltration. Moreover, our study demonstrated 
potentially chemopreventive effects of diet-derived PEITC by regulating key genes 
related to cell adhesion pathways. Results from our study supports previous findings 
demonstrating beneficial effects of PEITC under in vitro conditions as well as 
demonstrates unique sensitivities among various animal strains. The mechanistic 





Chapter 3: Toxic Effects of Dietary Indole-3-Carbinol: Intestine 
as the Target Tissue 
Abstract 
Indole-3-carbinol (I3C), a cruciferous vegetable-derived bioactive compound, 
is known for its potentially protective effects against chronic diseases. These benefits 
fostered its commercial availability as a dietary supplement. However, the safety of 
orally consumed I3C remains largely unresolved. In this study, immune-deficient 
BALB/c nu/nu male mice were fed an AIN-93 diet supplemented with 0- 100 µmoles 
I3C/g. Mice were biologically responsive to 10-100 µmoles I3C/g diets, 
concentrations used in previous studies. Mice fed 100 µmoles I3C/g diet were not 
viable after seven days. However, switching mice to the control diet without I3C after 
first detection of stress resulted in a 75% recovery rate. Mice fed 10-50 µmoles I3C/g 
survived but show concentration-dependent physical effects including lethargy, turgid 
skin, as well as blood within stool collections. The intestine appeared to be the target 
of I3C toxicity. Number and width of intestinal villi were significantly altered by I3C. 
Molecular analysis using Ki67, a proliferative marker and TUNEL assay, an 
apoptosis marker indicated a dose-dependent reduction in cell proliferation and 
increase in apoptosis, respectively. Other molecular effects of I3C include significant 
induction of CYP1A1 expression (200 fold) and other xenobiotic enzymes within 
livers of mice treated with 50 µmol I3C/g diet. These findings were similar to that 
found using human HepG2 liver cell culture model, further supporting involvement of 
aryl hydrocarbon receptor-mediated pathway in the metabolism of I3C.  This study is 
the first report of hazardous effects of I3C that are specific to the gastrointestinal tract 
and should serve as a caution for excessive use of I3C. 
Introduction 
Indole-3-carbinol (I3C) is a diet-derived, bioactive compound from 
cruciferous vegetables such as broccoli, Brussels sprouts, and cauliflower, generated 
from the hydrolysis of glucobrassicin by myrosinase (Broadbent & Broadbent, 




use of this natural dietary product to prevent or minimize chronic diseases such as 
cancer, inflammatory bowel disease, or to suppress secondary complications such as 
chronic inflammation (Meng et al., 2000; Reed et al., 2006; N. Takahashi et al., 1995; 
T. T. Wang et al., 2012). In vitro studies have shown I3C and its metabolites to have 
anti-tumorigenic properties by acting as aryl hydrocarbon receptor (AhR) ligands, 
inhibiting androgen receptor-mediated pathways and prostate cancer cell growth, anti-
angiogenic abilities to reduce tumor viability, as well as elicit effects specific to 
immune response and apoptosis (Tsai et al., 2010; T. T. Wang et al., 2012; Weng et 
al., 2007). Ability to activate or inhibit the expression of these biological pathways 
are thought to be major mechanisms exerted by I3C. However, the precise 
contrivances underlying the ability of I3C to promote healthful outcomes and prevent 
chronic diseases remain unclear.  
The perceived benefits of I3C on health have fostered its availability as a 
commercially available dietary supplement.  However, controversy exists between 
effective I3C concentrations on clinical and preclinical levels and the outcomes 
associated with consuming high quantities warrant further investigation. Clinical 
studies have shown tolerability of doses up to 1,200 mg I3C/day before adverse 
effects were evident (Reed et al., 2006). Phase 1 trials in women provided single and 
multi-doses of I3C supplements revealed no additional, observable benefits in doses 
greater than 1000 mg (Reed et al., 2006). However, there is a wide range of I3C doses 
used in rodent models ("Clinical development plan: indole-3-carbinol," 1996; 
Shertzer & Sainsbury, 1991b; Verschoyle, Steward, & Gescher, 2007). Overlaps in 
I3C’s effective health-promoting and toxic doses have made it difficult to distinguish 
no effect levels (NOELs) from chemopreventive ranges ("Clinical development plan: 
indole-3-carbinol," 1996). Genetic variability among subjects and metabolic 
efficiency among rodent species are contributing factors to the differential responses 
of I3C. This has led to the need to gauge short and long term effects of dietary 
consumption of I3C on various models by determining upper thresholds or limits 





Given that effective doses of I3C remain elusive, as a prelude to 
tumorigenesis study, we first evaluated the effects of dietary exposure to I3C utilizing 
immune-deficient BALB/C nu/nu male mice, a rodent model commonly used in 
tumorigenesis studies (Hudson et al., 2012; R. W. Li et al., 2013; T. T. Wang et al., 
2008). A range of 0 to 100 µmol I3C/g diet was chosen based on concentrations used 
in a previous study (Kassie et al., 2008). We hypothesized that I3C consumption up to 
100 µmol/g diet could be safely administered based on previous lab findings. 
Unexpectedly, I3C was found to be toxic. We further evaluated and characterized the 
pathophysiological and molecular effects of I3C. Qualitative and quantitative effects 
of dose-dependent consumption and sensitivity to I3C on the spleen, liver, kidney, 
and intestine of mice as well as physiological and molecular parameters were also 
examined to elucidate tissue targets and mechanisms.  
Materials and Methods 
Chemicals and Diets 
I3C (99% purity), dimethyl-sulfoxide (DMSO), and 10% neutral formalin 
buffer were purchased from Sigma-Aldrich Co. (Milwaukee, WI). Nutritionally- 
complete powdered AIN-93M diets with and without I3C (100 µmol/g diet) were 
prepared by Research Diets (New Brunswick, NJ) and stored at -20°C until weekly 
feedings. Formulation for control and treatment diets were based upon previous 
experiments that assessed quality and quantity of I3C in rodent diets (Kassie et al., 
2008). The diets containing 10 µmoles/g and 50 µmoles/g I3C were obtained using a 
1:10 and 1:2 dilution of 100 µmoles/g stock with 0 µmoles/g I3C control stock. All 
diets were thoroughly mixed before administration to the animals. 
Cells and Cell Culture 
HepG2, human hepatocellular carcinoma cells were purchased from the 
American Type Culture Collection (Manassas, VA) and grown in Dulbecco’s 




100 µg/ml streptomycin, and 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, 
CA). Cells were incubated at 37oC in the presence of CO2-air (5:95, v/v). 
in vivo RNA Extraction and Reverse Transcription (RT)-PCR Analysis 
HepG2 cells were trypsinized with 0.25% Trypsin-EDTA solution 
(Invitrogen). Then, seeded in conditioned media at a density of 0.25 x 106 cells/well 
in 6-well plates (Corning Inc., Corning, NY, USA), one day prior to treatment 
initiation. Fresh medium was replaced daily with treatment media containing 0, 1, 5, 
25 or 50 µM I3C. Cells were harvested for total RNA isolation after 48 hours using 
the TRIzol® method (Invitrogen) as described previously (Hudson et al., 2012). Real 
time reverse transcription polymerase chain reaction (RT-PCR) was used to quantify 
gene expression levels of human cytochrome P450 family 1, subfamily A, 
polypeptide 1  (CYP1A1), cytochrome P450 family 1, subfamily B, polypeptide 1 
(CYP1B1), cytochrome P450 family 2, subfamily D, polypeptide 6 (CYP2D6), 
cytochrome P450 family 2, subfamily C, polypeptide 9  (CYP2C9), and cytochrome 
P450 family 3, subfamily A, polypeptide 4  (CYP3A4). Human TATA binding 
protein (TBP) was used as a housekeeping gene for calculation of relative expression 
levels. 
Experimental Design and Animals 
All experimental protocols were in accordance with the National Institutes of 
Health guidelines and were approved by the USDA Animal Research Advisory 
Committee (BAACUC protocol # 12-030). Male athymic nude mice (BALB/c nu/nu, 
20-22 g, 5-7 weeks old) were purchased from Charles River (Frederick, MD) and 
were individually housed in filter-top cages at the USDA BHNRC animal facility. 
Room conditions were carefully monitored and held at a constant temperature of 22 ± 
1°C with a 12 hour rotating day and night cycle. Animals consumed food and filtered 
water ad libitum. Food consumption and body weights were recorded weekly. An 
acclimation period of 1 week prior to treatment feedings enabled mice to adapt to 




Animals assigned to one of four experimental feeding groups- (i) control diet, (ii) 
control diet with 10, (iii) 50, and (iv) 100 µmol I3C/g diets (n = 5/group). Mice 
remained on their respective diets for 4 weeks. The animals were then euthanized and 
necropsy was immediately performed. 
Animal Observations and Survival 
Animals were observed 2 times/week for changes in physical appearance, 
activity levels, food consumption and the presence of fecal blood. A 4-level scale was 
arbitrarily constructed to categorize the varying degree of activity levels into groups, 
as adapted from previously used methods (Morton, 2000; Nunamaker, Anderson, 
Artwohl, Lyubimov, & Fortman, 2013; Nunamaker, Artwohl, Anderson, & Fortman, 
2013; Paster, Villines, & Hickman, 2009; van Vlissingen, 1999). An activity level of 
++++ represents very active, normal animal behavior. +++, represents a slightly 
reduced, active activity level or with mild gait. ++ represents an abnormal activity 
level, in which the animal is moving very slowly or with a severely altered gait and + 
represents lethargy or very reluctant to move more than 3 or 4 steps. 0, represents 
complete inactivity or animals were awake but did not move. Animals were 
monitored by trained animal care staff as appropriate for species-specific signs of 
pain and distress, in accordance with the National Institutes of Health guidelines and 
were approved by the USDA Animal Research Advisory Committee. Cage-side 
observations were completed by a primary observer and confirmed by secondary 
observers of trained research staff throughout the duration of the study. 
in vivo RNA Isolation and RT-PCR 
Livers were harvested and stored in RNAlater (AMBION Inc., Austin, TX) 
immediately following necropsy and frozen until analysis. For determination of 
mRNA expression in liver samples, total RNA was isolated and purified using 
RNeasy kit (Qiagen Inc., Valencia, CA), according to manufacturer’s protocol. Gene 
expression was quantified using a previously described TaqMan real-time RT-PCR 
method (Y. Takahashi et al., 2006). TATA box binding protein (Tbp), cytochrome 




subfamily C, polypeptide 55 (Cyp2c55), cytochrome P450 family 2, subfamily D, 
polypeptide 10 (Cyp2d10), cytochrome P450 family 3, subfamily A, polypeptide 11 
(Cyp3a11), UDP glucoronosyltransferase 1 family, polypeptide A1 (Ugt1a1), 
NAD(P)H dehydrogenase, quinine 1(Nqo1), and TaqMan gene expression assay 
primers and probes were purchased from Applied Biosystems (Foster City, CA). 
TBP, a housekeeping gene, was used to calculate relative gene expression levels in 
mouse liver samples. 
Immunohistochemical (IHC) Preparation and Analysis of Results 
Tissue samples were prepared for in situ immunohistochemical analysis 
according to a previously discussed method (T. T. Wang et al., 2008). Liver, kidney, 
spleen, and proximal, middle, and distal intestinal sections were immediately 
removed following euthanization and placed in a 10% neutral buffered formalin 
fixative agent. Spleens were harvested from all treatment groups with the exception 
of animals treated with 100 µmol I3C/g diet. Tissues were stored in formalin for 
approximately 72 hours prior to slide preparation. Cross-sectional and longitudinal 
tissue sections were cut approximately 4-5 microns thick and stained with 
hematoxylin and eosin, or colorimetric Ki-67 proliferation marker. TUNEL assay was 
performed with modifications using an ApoTag kit (Millipore), as previously 
described (Berry & Baehrecke, 2007; Lee & Baehrecke, 2001; S. L. Wang, Hawkins, 
Yoo, Müller, & Hay, 1999). Slides were then cover slipped with mounting medium 
and stored in a dark location at room temperature until analysis.  
All IHC slides were viewed on an Olympus light microscope (Olympus 
Optical Co., Japan) and images were acquired using Nikon D7000 digital SLR 
camera (Nikon Inc., Melville, NY). Images were viewed with Nikon Camera Control 
Pro 2 software, Version 2.8.0 (Nikon Inc., Melville, NY). Parameters for image 
analysis include: (1) all images were taken at a constant exposure; (2) images were 
acquired pseudo randomly with no area overlapping; (3) all images were acquired 
using 400x magnification (or 40x magnification for TUNEL and Ki67 analysis); (4) 
images of 10 fields were randomly taken for each slide and average data is reported. 




Intestinal villi data was recorded as raw area in inches squared and relative percent 
composition of each treatment group was used for analysis. 
Statistical Analysis 
The 5 animals per treatment group provide at least 85% power to detect 
effects and provide > 95% to detect differences as small as 10%. Statistical One-Way 
Analysis of Variance (ANOVA) followed by post hoc analysis using Bonferoni’s 
Multiple Comparison Test were conducted to determine the differences among means 
using SPSS for Windows (version rel. 10.0.5, 1999, SPSS Inc., Chicago, IL). Means 
were reported as mean ± SEM. Statistical significance was declared at p < 0.05. 
Kaplan-Meier analysis was used to calculate survival rates among treatment using 
GraphPad Prism 5 for Windows (version rel. 5.01, 2007, GraphPad Software, Inc., La 
Jolla, CA) and results were displayed as percentages. Power calculations were 
completed using SAS 9.3 (version 6.1.7601, 2010). 
Results 
I3C at 100 µmol/g is Toxic 
 
Treatment Group General Appearance Activity Level Fecal Blood 
Control Pink skin, clear eyes Very active (++++) None   
10 µmol I3C Pink skin, clear eyes Very active (++++) Yellow with red 
tinge 
50 µmol I3C Dull pink skin Somewhat active (++) Dark red, dense  
100 µmol I3C Pale, dull skin Lethargic/inactive (+) Dark, dense, 
covered majority of 
cage  
Recovery Pink skin, clear eyes Active (+++) None present 
following week 1 
on control diet 
 
Table	  2 Physical observations of athymic mice fed control and treatment (10- 100 µmol I3C/g ) diets.	  Mice 
were observed intermittently 2 times per week. Final results are recorded at week 5 of study. Results are reported 
as average observation per treatment group. n = 5 animals/treatment group. Activity level: ++++, very active; +++, 





Changes in physical appearance, activity levels, and stool abnormalities were 
found in animals consuming > 50 µmol I3C/g diet. The most severe phenotypic 
effects occurred in mice fed 100 µmol I3C/g diets and the deleterious effects of I3C 
were observed within 24 hours of treatment initiation (Table 2). After 72 hours of 
treatment, animals fed the highest dose had visible skin flush, lethargy, and blood 




Figure 11 Survival Rates of Athymic Mice Treated with 0- 100 µmoles I3C/g diet. Results were reported as 
percentages. n = 5 animals/treatment group 
Effect of Lower I3C Concentrations on Animal Survival 
 
 
Figure 12 Body Weight Measurements and I3C-powdered Diet Intake in Athymic Mice. Mice were 
randomized into two groups and fed either control or 100 µmol I3C/g diets for 1 week. Mice originally fed with 
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100 µmol I3C/g diet were switched to control diet and animals fed control diet were subdivided into 4 
experimental groups- control, 10, 50, and 100 µmol I3C/g diet, with 5 animals per group. Mice remained on their 
respective diets for 4 additional weeks. Body weight (g) and food consumption (g) were recorded weekly. A) 
Mean weekly body weights of mice fed control or treatment diets. B) Mean weekly food consumption of mice fed 
control or treatment diets. Values are reported as means ± SD. (*) represents significant differences between 
control and treatment groups at p < 0.05. 
Animals fed 10 and 50 µmol I3C/g diets survived through the entirety of the 
study. No significant differences were found in the amount of food consumed (g) 
between mice fed control and I3C- containing diets (Fig. 12). However, significant 
weight loss occurred in mice fed 50 µmol I3C/g diet compared to animals assigned to 
control group (Table 2).  
Changes in physical appearance, activity levels, and stool abnormalities were 
also found in animals fed I3C containing diets. Mice consuming 50 µmol I3C diets 
exhibited pale skin color and blood in the feces. With the exception of slight rusty red 
color in urine/ fecal matter, mice fed 10 µmol I3C/g diet had no overt differences in 
appearance compared to animals fed control. 
Toxicity Effect of I3C can be Reversed 
Discontinuing high concentration diets (100 µmol/g) upon detecting stress (at 
72 hours) and switching mice to the control diet resulted in recovery with a 75% 
survival rate (Fig. 11). After 4 weeks of continuous feeding on control diet, animals 
showed similar activity as well as phenotypic (skin color, fecal color) signs as the 
animals fed control diet. 
Toxic Effect of I3C is due to Intestinal Damage 
To elucidate the mechanisms, hematoxylin and eosin staining of intestine, 
spleen, kidney, and liver revealed the gastrointestinal tract as the primary affected 
tissue. No obvious differences were found in spleen, kidney, or liver morphology in 





Figure 13 Intestinal Villi of Athymic Mice. Changes in intestine villi of mice treated with 0 to 100 µmol 
I3C/g diet were examined by immunostaining with hematoxylin and eosin at x4 magnification (a 0.17 mm2 field). 
Proximal, middle, and distal intestinal villi A) number, B) height, and C) width of control and treatment mice. 
Villi number values are reported as mean ± SE. Differences in villi height and width were reported as % control.  
n= 3 animals per treatment group. (*) represents significant differences between control and treatment groups at p 
< 0.05 
In the gastrointestinal tract, animals fed I3C had a significantly lower number of 
villi. A dose-dependent reduction in average villi number was observed in mice fed 
10, 50, and 100 µmol I3C/g diets compared to control treatment group. Compared to 
the control, animals treated with the 10 µmol I3C/g diet had an average of 1.7 ± 3.3, 1 
± 5.7, and 9.5 ± 4.4% less villi in the proximal, middle, and distal intestinal regions, 
respectively. Our analysis also revealed significant decreases in intestinal villi 



































































































































































































































































38 ± 4.1% in the distal regions of mice treated with 50 µmol I3C/g diet. Additionally, 
those treated with the 100 µmol I3C/g, incurred a 35.5 ± 8.1%, 43.1 ± 6.6% and 44.1  
± 13.6% loss of villi in the proximal, middle, and distal regions, respectively (Fig. 
13).  
A dose-dependent increase in villi height and significantly larger and wider villi 
were also observed in mice fed I3C-containing diets than villi of mice fed control 
diets (Fig. 13). Animals fed 10 µmol I3C/g diet had average villi heights of 5.8 ± 
4.77% and 5.4 ± 3.6% longer than control animals in the proximal and middle 
regions, respectively. A 5 ± 3.3% average villi shortening in the distal region of mice 
fed 10 µmol I3C/g diet. 6.3 ± 4.3% and 12.5 ± 4.7% increases in height were 
observed in the proximal and middle regions with an 8.8 ± 6% shortening in the distal 
intestinal region were found in mice treated with 50 µmol I3C/g diet. Moreover, an 
average increase in width by 45.4 ± 9.1%, 20.7 ± 12.1, and 55.8 ± 13% was found in 
the proximal through distal regions in mice fed 10 µmol I3C/g diet. For animals 
provided 50 µmol I3C/g diet, intestinal widths were 91.7 ± 12.2%, 46.6 ± 11.7, and 
32.7 ± 13.5% larger in the proximal, middle, and distal regions, respectively, than the 
control group. Those fed the highest dose had villous shortening of 42.7± 3.4% within 
the proximal region, 44 ± 5.4% in the middle region, and 3.6 ± 5% in the distal region 
as compared to the control diet animals. Moreover, those animals fed the highest dose 
had a decrease in villi width of 22.2 ±13.6% in the proximal region, 25 ± 10.3% in 
the middle region compared to control diet (Fig. 13). Width changes in distal region 





Figure 14 Ki67 and TUNEL analysis of Athymic Mice Intestine. Apoptotic and proliferative changes in 
intestine villi of mice treated with 0 to 50 µmol I3C/g diet were examined by immunostaining with Ki67 and 
TUNEL assay at 40x magnification (a 0.17 mm2 field). A) Ki67 quantification of proximal, middle, and distal 
intestinal villi. B) TUNEL analysis of proximal, middle, and distal intestinal villi of control and treatment mice. 
Differences in Ki67 positive staining were reported as a relative proliferative index.  Values are reported as mean 
± SE. n= 3 animals per treatment group. (*) represents significant differences between control and treatment 
groups at p < 0.05.  
The effects of indole-3-carbinol on apoptosis and proliferation within the 
gastrointestinal tract of mice were also examined to provide molecular mechanisms 
that lead to changes in intestinal villi. Gradient changes in positive Ki67-stained 
nuclei, a proliferation marker, were observed in the proximal and middle intestinal 
regions of mice fed 10 and 50 µmol I3C/g diet (Fig. 14A). TUNEL method was used 
to detect apoptosis-mediated DNA breaks and DNA fragmentation.  We found 
significant increases in TUNEL positive nuclei in the proximal and middle intestine 


















































































































































































































Immunohistochemical results of the recovery treatment group, which was initially 
fed 100 µmol I3C/g diet for 72 hours then switched to control diet for the remainder 
of the feeding study, were examined. At the end of treatment, there were no 
significant differences in spleen, kidney, liver morphology when compared to control 
group. Overall, investigation of gastrointestinal tract stained with hematoxylin and 
eosin revealed slight but significant changes in the number, length, or width of villi in 
comparison to those fed control diets for the entirety of the study. Assessing for 
changes against Ki-67 marker noted significant decreases in proliferation by 33.3 ± 
3.2 and 44.3 ± 3.7% of the proximal and middle intestinal regions, respectively. No 
significant proliferative differences were found in the distal region nor were 
significant changes in apoptotic rates of intestinal cells observed. While the recovery 
group resembled physical appearances of the control group, their intestinal changes 
closely resembled results of either the 10 or 50 µmol treatment groups. Taken 
together, these results further support findings of intestinal damage reversal as a result 





























































































































































Figure 15 Effects of Indole-3-carbinol on xenobiotic metabolizing enzyme gene expression in mice liver 
tissue. Gene expression of Phase 1 and -2 xenobiotic metabolizing enzymes, A) Cyp1a1; B) Cyp3a11; C) 
Cyp2c55; D) Cyp2d10; E) Nqo1; and F) Ugt1a1, was assessed. RT-PCR analysis was conducted on stabilized 
RNA from livers of mice treated with 0- 50 µmol I3C/g diet and Recovery treatment groups. Recovery treatment 
group consisted of animals given 100 µmol I3C/g diet and subsequently fed control diet for the remainder of the 
study. Relative mRNA levels of each group are expressed as means ± SE (n=5 per treatment group). (*) represents 
significant differences between control and treatment groups at p < 0.05. 
Effects of I3C on mRNA levels of phase-1 enzymes Cyp1a1, Cyp3a11 and 
Cyp2c55, mouse homologs of CYP3A4 and CYP2C9, as well as phase-2 enzymes, 
Ugt1a1 and Nqo1 were determined to further understand the metabolic pathway 
activated by consuming I3C. Significant gene induction for all Phase 1 enzymes in 
mouse liver was seen at doses as low as 10 µmol I3C/g diet (Fig. 15). Significant 
Phase 2 induction was observed in livers of mice treated with 50 µmol I3C/g diet at 
11.06 ± 2.69 and 11.25 ± 1.74 fold changes for Ugt1a1 and Nqo1, respectively. There 






Figure 16 Effects of Indole-3-carbinol on xenobiotic metabolizing enzyme gene expression in HepG2 cells. 
RT-PCR analysis was conducted on stabilized RNA from HepG2, human hepatocarcinoma cells treated with 0- 50 































































































































µmol I3C/L media for 48 hours. Gene expression of Phase 1 and -2 xenobiotic metabolizing enzymes, A) 
CYP1A1; B) CYP3A4; C) CYP1B1; D) CYP2C9; E) CYP2D6; and F) NQO1, was assessed. Relative mRNA 
levels of each treatment group are expressed as means ± SE (n=6 per treatment group). (*) represents significant 
differences between control and treatment groups at p < 0.05. 
Gene regulation of drug metabolizing enzymes was also assessed in HepG2, a 
human hepatocarcinoma cell line as a comparison to the mouse data. For CYP1A1, 
there was a concentration-dependent induction of CYP1A1 mRNA level and the 
effect occurred at concentrations as low as 5 µM (Fig. 16).  
In HepG2, a significant dose-dependent inhibition of Phase 1 enzymes, CYP1B1 
and CYP2C9, was observed at a dose of 1 µM (Fig. 16).  Additionally, inhibition of 
CYP3A4 mRNA expression occurred at 50 µmol/L while CYP2D6 gene expression 
was not substantially altered (Fig. 15). Small but significant induction of NQO1 
mRNA expression was observed in HepG2 by 1.4 ± 0.1 and 1.6 ± 0.1, when treated 
with 25 and 50 µM I3C (Fig. 16). 
 
Discussion 
In this study, we demonstrate that I3C exerts tissue-specific effects on an 
athymic mouse model. Key findings from this study including sensitivities of mouse 
fed I3C; tissue damage primarily localized to the intestine; and changes in cell 
proliferation and apoptosis in intestine, appeared to be the mechanisms. Additionally, 
differential induction of xenobiotic metabolizing enzymes occurred in livers of 
athymic mice as a result of consuming dietary I3C was observed.  
Contrary to studies utilizing similar dosage of I3C, our data indicates 
significant changes in weight (Fig. 12) (Kassie et al., 2008). Weight loss in our study 
may be due to palatability changes, perturbed metabolic functioning (Kassie et al., 




study, the amount of I3C administered to the animals ranged from approximately 
202.7 µmol to 2.03 mmol I3C/kg body weight Human Equivalent Doses (HED), 
which is similar to amounts used in other experimental animal studies (Dagne et al., 
2011; Kassie et al., 2010; Reagan-Shaw, Nihal, & Ahmad, 2007).  At these 
administered levels, changes in physical activity and the presence of fecal blood were 
dose-dependent and linear. These observations are consistent with previous studies 
that report severe lethargy following I3C feedings, as indicated by hunched postures 
and decreased movement compared to animals fed on control diets (Kantachuvesiri et 
al., 2001; Mitchell et al., 2006; Patterson, Mullins, & Mitchell, 2008; Prieto et al., 
2011). The most substantial changes and signs of lethargy were observed in animals 
fed 50-100 µmol/g diets (Table 2). Moreover, fecal blood was observed in I3C as low 
as 10 µmoles/g, a concentration comparable to orally administered doses of I3C in 
Phase 1 clinical trials (Dagne et al., 2011; Reed et al., 2006; Reed et al., 2005). Our 
results suggest potential hazards in consuming I3C. The reasons underlying the 
disparity in results from our study versus published literature that did not report toxic 
effects are unclear. However, it is possible that these differences are also influenced 
by mouse strain variance.  
There are limited documented studies on direct intestinal damage of I3C. Our 
immunohistochemical analysis revealed morphological changes that were localized to 
the intestine and not grossly detected in other tissues such as the spleen, liver, or 
kidney of the I3C treated mice. Significant yet reversible, general villous atrophy 
occurred in all intestinal regions after 4 weeks (Fig. 13). Mechanistically, the effects 




as indicated by TUNEL and Ki67 staining (Fig. 14). These changes are also 
consistent with increased intestinal villi width and height (Fig. 13).  
In general, dietary exposure to I3C in moderate to high doses may induce 
certain phase 1 and 2 xenobiotic metabolizing enzymes (Bonnesen, Eggleston, & 
Hayes, 2001; Nho & Jeffery, 2001). In vivo results from this study revealed a 
significant dose dependent increase in homologue gene expression of Cytochrome 
P450 1A1, -3A4, -2C9, -2D6 as well as Phase 2 enzymes, UGT1A1 and NQO1 upon 
dietary administration of I3C (Fig. 15). This panel represents genes primarily 
involved in approximately 90-95% of all xenobiotic metabolism in humans as related 
to the detoxification polycyclic aromatic hydrocarbons from chemical waste and other 
organic materials as well as steroid hormones (Sangar, Bansal, & Avadhani, 2010). 
Conversely, we found that I3C significantly altered the HepG2, human liver cancer 
cell line expression patterns of both Phase 1 and 2 homologue genes (Fig. 16). We 
found similar in vitro and in vivo induction of CYP1A1 but not other enzymes. The 
differences in gene expression could be due to the distinct biology of the liver cancer 
cells for the in vitro studies versus mouse liver cells; and the duration of compound 
administration (short term exposure in in vitro models versus chronic dosing in the 
animal study) (Kassie et al., 2010). Further studies are necessary to elucidate the 
significance of CYP1A1 gene induction in the metabolism of I3C. 
Conclusion 
In summary, we found intestinal damage in animals receiving I3C 
supplementation as low as 10 µmol/g diet. This is a concentration comparable to 




demonstrated that the potentially toxic effects of diet-derived indole-3-carbinol 
appeared to be specific to the gastrointestinal tract. Our study should serve as a 
caution for excessive use of I3C in human and future studies with I3C on 






Chapter 4: Inhibition of LNCaP, Human Prostate Carcinoma 
Xenograft Tumor Growth by Dietary Administration of Indole-
3-carbinol is associated with Inhibition of Xenobiotic 
Metabolism and Integrin Pathways 
Abstract 
Indole-3-carbinol (I3C), a bioactive compound found in cruciferous 
vegetables, has been shown to possess protective properties against chronic diseases 
and associated conditions. In previous studies, I3C has exhibited suppressive effects 
within the tumor microenvironment by diminishing growth and reducing surrounding 
inflammation. However, the exact mechanism in regulating tumor growth remains 
unclear. In the present study, tumor volume of androgen-dependent, LNCaP, human 
prostate carcinomas was significantly reduced in immunodeficient mice (6- 8 weeks 
old, male, Balb c/c nu/nu) fed physiologically relevant dosages of I3C (0.1 and 1 
µmoles I3C/g AIN-93 diet). Tumor analysis revealed a 49.7% decrease in tumor 
volume within the groups fed 0.1 and 1 µmoles I3C/g diet. Alterations in gene 
expression were assessed in tumor and liver samples. Consistent with previous 
results, treatment with I3C significantly upregulated Phase 1 xenobiotic metabolizing 
enzymes. Moreover, reduced expression of integrin genes were observed in mice fed 
1 µmole I3C/g. Results from this study has shown that I3C may reduce the likelihood 
of prostate cancer progression by stimulating xenobiotic metabolism and modulating 
tumor adhesion properties. 
Introduction 
Prostate cancer is the most common, non-skin cancers in America, in which 1 
of every 6 men are affected (Edwards et al., 2013). Many lifestyle factors, such as 
diet and exercise, contribute to cancer incidence. Epidemiological studies focusing on 
dietary intake have shown a strong correlation between cancer risk and lack of 
vegetable consumption and variety (P. Gupta et al., 2014; Verhoeven et al., 1996; 
Zanini, Marzotto, Giovinazzo, Bassi, & Bellavite, 2014). This evidence supports the 




cruciferous vegetables is inversely proportionate to prostate cancer development 
(Arab et al., 2013; Kristal & Lampe, 2002). Moreover, the normal function of urinary, 
bowel, and sexual reproductive structures may be affected and disrupted by prostate 
cancer and its current treatment options (Diefenbach et al., 2012; National Cancer; 
Wilt, 2002). With the lack of effective treatments available for prostate cancer, the 
identification and use of natural, anti-carcinogenic bioactive compounds found in 
cruciferous vegetables have gained popularity. 
Indole-3-carbinol (I3C) is a dietary compound derived from glucobrassicin, a 
glucosinolate found in cruciferous vegetables. I3C is well known for its 
chemopreventive effects and has undergone various testing under clinical and 
preclinical settings (Huang, Jeffery, & Erdman, 2014; Souli et al., 2008). I3C has 
been shown to inhibit the development of epithelial tumors within the colon, lung, 
liver, breast, and prostate of humans in cell and animal models (Firestone & Sundar, 
2009). Moreover, I3C has been well tolerated in clinical studies with few adverse 
effects reported in patients taking pharmacologically-relevant dosage of I3C 
(McAlindon et al., 2001; Rosen, Woodson, Thompson, Hengesteg, & Bradlow, 1998; 
Wong et al., 1997).  
I3C exerts several effects that may contribute to cancer prevention (E. K. Kim 
et al., 2013). One mechanism involves the modulation of androgen-responsive 
proteins such as prostate specific antigen (PSA), which are key growth regulators. In 
cell culture, I3C modulates androgen metabolism and significantly suppresses the 
androgen receptor (AR) signaling via a ligand-dependent mechanisms (Hsu et al., 
2006; Hsu et al., 2005). I3C may also induce phase 1 and 2 xenobiotic enzymes and is 
considered a first line of defense against toxins within humans and animals 
(Aggarwal, Danda, Gupta, & Gehlot, 2009; Aggarwal & Ichikawa, 2005; Aggarwal & 
Shishodia, 2006). These changes may lead to increased catabolism and excretion of 
carcinogens and steroid hormones shown to promote cancer. Additionally, the role of 
integrins within the extracellular matrix of prostate cancer cells in growth, migration, 
and metastasis has been of particular interest (Fornaro et al., 2001; Goel, Li, Kogan, 
& Languino, 2008). Activation of integrins occurs by local stimuli like soluble 




Therefore, the potential of I3C to reduce integrin expression in androgen-dependent 
cell lines warrants further investigation.  
In recent studies from our lab, I3C has been shown to regulate androgen-
responsive gene expression under in vitro conditions (E. K. Kim et al., 2013; T. T. 
Wang et al., 2012). However, I3C has variable effects on multiple cell and animal 
models (Garikapaty, Ashok, Tadi, Mittelman, & Tiwari, 2006; Y. Li, Ahmad, Kong, 
Bao, & Sarkar, 2014; J. Zhang et al., 2003). Earlier research has focused on testing 
physiologically-achievable dosage of I3C in a lung cancer xenograft mouse model 
(Kassie et al., 2008). The exact mechanisms that underlie I3C-modulated events in 
vivo remains unclear. The purpose of this study is to take an initial step towards 
examining the physiological and biological effects of indole-3-carbinol on prostate 
cancer development in an athymic mouse androgen-dependent human prostate tumor 
xenograft model. The overall goal of this research is to determine if I3C can provide 
protection against prostate cancer, if consumed naturally through the diet. A 
secondary goal is to identify biomarkers and surrogate endpoints sensitive to the 
presence of I3C. The significance of this research could potentially enhance the 
utilization of this compound within whole food sources to improve the health status 
of the human population while enhancing the market value and variety of cruciferous 
vegetables within the agricultural industry 
Materials and Methods 
Cell Adhesion Assay 
LNCaP, prostate carcinoma cells were purchased from the American Type 
Culture Collection (Manassas, VA) and grown in RPMI 1640 media supplemented 
with 100 U/ml penicillin, 100 µg/ml streptomycin, and 10% fetal bovine serum (FBS) 
(Invitrogen, Carlsbad, CA). Cells were incubated at 37oC in the presence of CO2-air 
(5:95, v/v). LNCaP cells were trypsinized with 0.25% Trypsin-EDTA solution 
(Invitrogen) then seeded in conditioned media with I3C (0, 0.1, 1, 5, 25, and 50 
µmol/L media) at a density of 0.625 x 105 cells/well in 24-well plates (Corning Inc., 




plate surface and was determined by sulforhodamine B (SRB) assay (Hudson et al., 
2012; Skehan et al., 1990). 
Treatment Diet Composition 
During the course of the study, mice were provided powdered AIN-93M diets 
in the absence or presence of purified indole-3-carbinol (0.1 or 1 µmol/g diet). Diets 
were purchased from Research Diets (New Brunswick, NJ) and stored at -20°C until 
treatment initiation, as per manufacturer’s instructions. Formulation for control and 
treatment diets were based upon previous experiments that assessed quality and 
quantity of I3C in rodent diets (Kassie et al., 2008). 
Animals were fed 0, 0.1, and 1 µmol I3C/g diet for the duration of this study. 
A dose of 1 µmol I3C/g diet in mice equates to a dietary intake of 2.98 mg I3C/kg 
body weight. A dose of .1 µmol I3C/g diet in mice equates to a human equivalent 
dose of 2.98 mg I3C/kg body weight. If estimating for a 60 kg man, the amount of 
I3C provided in the lower dose may correspond with consuming approximately 1.72 
cups/ cruciferous vegetable.  Moreover, in a clinical study, administration of I3C 
supplements was tolerated in doses up to 1,200 mg/day in male and female cancer 
patients (Reed et al., 2005). Therefore, the two doses selected for this study assessed 
the effects of tumorigenesis on I3C concentration similar to amounts consumed in the 
diet as well as amounts supported on a low dose chemopreventive range. In 
preclinical tumorigenesis studies, mice showed protection against cancer in diets 
supplements with 0- 100 µmol I3C, ranges that were considered approximately, 1000 
and 100 times higher than the concentrations used in this study, thereby, deeming the 
concentrations of 0.1 and 1 µmol I3C/g diet used in this study, as safe, cautious, and 
physiologically relevant dosages. 
Tumor Xenograft Model 
LNCaP (American Type Culture Collection, Manassas, Virginia), an 
androgen-dependent human prostate carcinoma cell line is used to model response to 
dietary administered I3C. Prior to inoculation, LNCaP cultures were grown in RPMI 




µg/ml streptomycin purchased from Invitrogen (Carlsbald, CA). Cultures were 
incubated in an atmosphere composed of 5% CO2 at 37°C.  
All experimental protocols were in accordance with the National Institutes of 
Health guidelines and were approved by the USDA Animal Research Advisory 
Committee. Male athymic nude mice (BALB/c nu/nu, 20-22 g, 6-8 weeks old) were 
purchased from Charles River (Frederick, MD) and were individually housed in filter-
top cages at the USDA BHNRC animal facility. Room conditions were carefully 
monitored and held at a constant temperature of 22 ± 1°C with a 12 hour rotating day 
and night cycle. Animals consumed food and filtered water ad libitum. Food 
consumption and body weights were recorded weekly. An acclimation period of 1 
week prior to treatment feedings enabled mice to adapt to control AIN-93M diet and 
environment. Animals were then, randomized into three experimental feeding groups- 
(i) control diet, (ii) control diet with .1, and (iii) 1 µmol I3C/g diets (n = 15/group). 
Two weeks following treatment initiation, all mice were inoculated via subcutaneous 
injection into the right and left flanks with LNCaP cell suspension. Cell suspension 
consisted of LNCaP cells at a density of 2 x 106 with 50 µl of phosphate-buffered 
saline (PBS) and an equal volume of Matrigel (BD Biosciences, Mansfield, MA). 
Injection sites and tumor volume (cm3) were monitored and measured weekly for 
palpable tumor growth and biological efficacy: (cm3) = 0.523 x [length (cm) x width2 
(cm2)] (Hudson et al., 2012; Kleinman & Martin, 2005). Mice remained on their 
respective diets for 7 weeks following inoculation.  
Plasma and Tissue Collection 
At the end of the study, mice were euthanized using a CO2 chamber and 
necropsy was immediately performed. Blood was collected, stored in vials coated 
with potassium EDTA solution (15% w/v), and placed on dry ice until plasma 
separation. Plasma were separated via centrifugation at 1500 rpm for 30 min at 4°C. 
Soft tissue including tumor, liver, kidneys, and spleens were collected and 
subdivided. Subdivided samples were immediately frozen in liquid nitrogen for 




AMBION Inc. (Austin, Texas). Samples were stored in an  -80°C freezer until further 
analysis. 
RNA Isolation and Reverse-transcription (RT)-PCR 
For determination of mRNA expression in tumor and liver samples, total RNA 
was isolated and purified using RNeasy (Qiagen Inc., Valencia, CA), according to 
manufacturer’s protocol. StrataScript First Strand complementary DNA Synthesis kit 
from Stratagene (Santa Clara, CA) was used to reverse-transcribe mRNA to 
complementary DNA. Real-time PCR were performed on Applied Biosystems 7900T 
Real-Time PCR System using TaqMan® Gene Expression Assay (Carlsbad, CA). 
Relative mRNA levels for analysis of gene expression changes were quantified using 
ΔCt method, as previously described TaqMan real-time RT-PCR method (E. K. Kim 
et al., 2013; Yuan et al., 2006). TATA box binding protein (TBP), a housekeeping 
gene, was used to calculate relative gene expression levels in soft tissue samples.  
Table 3 Marker genes for pathways related to carcinogenesis  
Pathway Human Mouse 
Proliferation KI67  
Cell Cycle CDKN1a, CDKN1b  
Androgen PSA  
Inflammation IL1RN Il-1β 
Monocyte Attraction CCL2  
Xenobiotic Metabolism  Cyps, Nqo1, Ugt1a1 
Cell Adhesion Integrins, FN1  
 
Protein Analysis 
In order to confirm or identify post-translational changes of mRNA level gene 
changes, two protein analysis methods were utilized. Immunohistochemistry was 
used to identify protein level changes in soft tissues. ELISA was utilized to analyze 




was determined using ELISA. Assays were performed using a commercial kit 
according to manufacturer’s protocols (eBioscience, San Diego, CA). 
Hypothetical Tumor Size Analysis 
Collected tumor volume data was fitted into an exponential growth equation, 
previously used by Li., et al (R. W. Li et al., 2013). The best fit values of START and 
K from the equation, Y = START x EXP (K x Y), was used to generate hypothetical 
tumor growth curves to depict stimulatory growth following 20 weeks of treatment. 
All data calculations were performed using Prism 6 software (GraphPad Software, 
San Diego, CA). 
Statistical Analysis 
The 15 animals used per group give >95% power to detect effects with at least 
a 10% magnitude. Mean body weights, food consumption, and tumor growth were 
used in the preliminary assessment of treatment groups. All end point assays were 
conducted in triplicate and averaged for group analysis. Means were reported as mean 
± SEM. One-Way Analysis of Variance (ANOVA) and Bonferroni test were 
conducted to determine the differences among means. Statistical significance was 
declared at p < 0.05 using SPSS for Windows (version rel. 21.0, SPSS Inc., Chicago, 
IL) and GraphPad Prism 5 for Windows (version rel. 5.01, 2009, GraphPad Software, 
Inc., La Jolla, CA). Power calculations were completed using SAS 9.3 (version 
6.1.7601, 2010). 
Results 
Effects of I3C on Body Weight and Food Consumption 
Prior to tumor injection, diet tolerance was assessed. Animals were observed 
for gross signs of diet-related toxicity, and a baseline line of food consumption was 
established. Overall, there were no significant differences in body weight or food 
consumption over the course of I3C administration (Fig. 17). However, trends in 




significantly grew in size. Changes in weight may be due to cancer-related cachexia 
as tumor burden increased for the animals.  
 
 
Figure 17 Body weight and dietary intake of treated mice. Mice were randomized into three groups and fed 0, 0.1, 
and 1 µmol I3C/g diet. Mice remained on their respective diets for 10 weeks. Body weight (g) and food 
consumption (g) were recorded weekly. A) Mean body weights of mice fed control or treatment diets. B) Mean 
weekly food consumption of mice fed control or treatment diets. Values are reported as means ± SD. (*) 
represents significant differences between control and treatment diets at p < 0.05. 
I3C Intake Perturbs Tumor Formation and Growth 
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Figure 18 Tumor growth and formation in treatment mice. LNCaP human prostate cancer cell xenografts was 
established in athymic nude mice. Tumor volume was measured weekly and calculated in described Materials and 
Methods section. A) Mean tumor volume and B) mean number of tumors formed in control and treatment mice 
during 10 week treatment period. C) Hypothetical tumor size after 20 week treatment period using tumor growth  
(Fig. 18A). Growth through 20 weeks was simulated for treatment groups using exponential growth equation in 
Materials and Methods section. Values are reported as means ± SD. (*) represents significant differences between 
control and treatment diets at p < 0.05. 
Significant decreases in tumor load were observed at week 8, in which tumor 
volume was 49.7% lower in the 0.1 and 1 µmol/g diet treatment groups (Fig. 18A). It 
is also possible that I3C treatment inhibited tumor formation prior to 3 weeks 
following LNCaP injection. Average tumors formed by the end of the study was 46.4 
and 42.3% lower in mice fed 0.1 and 1 µmol/g diets, respectively (Fig. 18B). 
Effect of I3C on androgen-responsive, proliferation, cell cycle, and inflammatory 
pathways 
Previous studies have demonstrated I3C’s role in modulating androgen-
responsive, proliferation, or inflammation pathways. Thus, we evaluated whether 
delayed tumor growth would affect related biomarkers (PSA, KI67, IL1RN, IL1β, 
and CCL2) following I3C treatment.  
Although there are appreciable trends in the data suggesting a significant role 
in the regulation of these pathways, treatment with I3C did not significantly affect 
these biomarkers with the tumors or circulating levels of Il-1β in the plasma (Figs. 
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19-20). One reason for these results may be due to I3C has been shown to affect 
protein expression without altering gene transcription. Other reasons may involve the 
complexity of the tumor environment since previous studies have demonstrated 
significant results in these genes in in vitro experiments or at higher concentrations of 
administered I3C in vivo. Therefore, further analysis can be done to identify whether 
other related genes were affected by treatment and if post-translational modifications 
could affect protein-level changes of the tested genes and contribute to the overall 
tumor attenuation.  
 
Figure 19  Various genes related to androgen responsive, proliferation, and inflammatory pathways 
assessed in athymic nude mouse model. Changes in mRNA expression of androgen-responsive, cellular 
proliferation, and inflammatory pathways were assessed in LNCaP prostate cancer cell xenografts in athymic nude 
mice. Real-time PCR analysis of PSA, KI67, Ccl2, CDKN1α, CDKN1β, IL1RN, and IL-1β was performed as 
described in the Materials and Methods section. Values are reported as means ± SD. (*) represents significant 










































































































































Figure 20 Effect of indole-3-carbinol on circulating Il-1β levels. Circulating Il-1β protein levels in plasma of mice 
treated with 0, 0.1, and 1 µmol I3C/g diet was assessed using ELISA as previously described in Materials and 
Methods section. n = 7 animals/treatment group. Results are reported as means ±SE. (*) represents p < 0.05. 
Effect of I3C on Xenobiotic Metabolism 
The effects of low dose I3C treatment on hepatic xenobiotic clearance were 
assessed. I3C has been previously shown to induce gene expression of Phase 1 and 2 
xenobiotic enzymes. Cyp1a1, Cyp2c55, Cyp3a11, Cyp2d10, and Phase 2 enzymes 
Ugt1a1 and Nqo1 were examined. These Phase 1 enzymes are mouse homologues of 



























Figure 21 Xenobiotic metabolizing enzyme gene changes in livers of athymic nude mice. Changes in mRNA 
expression of Phase 1 and -2 xenobiotic metabolizing enzymes were assessed in LNCaP prostate cancer cell 
xenografts in athymic nude mice provided dietary administered I3C. Real-time PCR analysis of A) Cyp1a1, B) 
Cyp3a11, C) Cyp2c55, D) Cyp2d10, E) Nqo1, and F) Ugt1a1 was performed as described in the Materials and 
Methods section. Values are reported as means ± SE. (*) represents significant differences between control and 
treatment diets at p < 0.05. 
Treatment with 1 µmol I3C/g diet was able to significantly induce expression of 
Phase 1 xenobiotic metabolizing enzymes (Fig. 21). Cyp1a1, -2c55, and -2d10 
expression was significantly altered following treatment with low dose I3C. As 
compared to the control group, Cyp1a1 expression was 2 ± .6 and 3.5 ± .7 times 
higher in the 0.1 and 1 µmol/g treatment groups, respectively. Average change for 
Cyp2c55 in the 0.1 and 1 µmol/g treatment group was Cyp2d10 expression was 1 and 
1.73 ± .2 times higher in the 0.1 and 1 µmol/g diet groups. UGT1A1 and NQO1 
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phase 2 enzyme induction potential has been seen in indole glucosinolates (Fahey et 
al., 1997; Shapiro et al., 1998). 
I3C Attenuates Cell Adhesion in vitro 
I3C’s ability to alter cell adhesion was assessed under in vitro and in vivo 
conditions. The results of the in vitro cell adhesion assay indicated linear, dose-
dependent inhibition with increasing concentration of I3C (Fig. 22). Significant 
decreases in cell adhesion were observed at concentrations of 25 µmol/L or greater. 
Next, cell adhesion was assessed on transcriptional level in LNCaP human prostate 




Figure 22 Changes in LNCaP cell adhesion following  I3C treatment in vitro. LNCaP cells were plated in 24-well 
plates in the presence of 0, 0.1, 1, 5, 25, and 50 µmol I3C/L media. After overnight incubation, cell attachment to 
the plate was assessed using SRB method as described in Materials and Methods section. Values are reported as 
means ± SE. (*) represents significant differences between control and treatment diets at p < 0.05. 
 
Integrin changes were also assessed under in vitro conditions. There were no 
significant changes in integrins A2, A5, and B1 (Fig. 23). However, significant 30% 
reduction in integrin A6 gene expression was observed in doses ≥ 25 µmol I3C/L 
Cell Adhesion Assay



















media. Integrin gene changes were also assessed in vivo. Following treatment with 
low dose I3C, ITGB1 expression was significantly inhibited by 26.4% in tumors of 
mice treated with 1 µmol I3C/g diet (Fig. 24). 
 
Figure 23 Changes integrin gene expression within LNCaP cells following in vitro treatment with I3C. LNCaP 
cells were plated in 6-well plates in the presence of 0, 0.1, 1, 5, 25, and 50 µmol I3C/L media. After overnight 
incubation, cells were harvested and RNA was harvested. Levels of ITGA2, ITGA5, ITGA6, and ITGB1 mRNA 
was quantified relative to TBP by RT-PCR as described in Materials and Methods section. Values are reported as 
means ± SE. (*) represents significant differences between control and treatment diets at p < 0.05. 
The results of integrin gene expression led to further exploration into tumor 
interactions with the ECM. In the plasma, fibronectin, a glycoprotein, involved in cell 
adhesion and migration, is present in a soluble dimeric form. It is also found in 




























































































multimeric form at the cell surface and in extracellular matrix, and serves a ligand for 
the integrins. Fibronectin 1(FN1) is responsible for binding to cell surfaces and 
various compounds including collagen, fibrin, heparin, DNA, and actin. Indole-3-
carbinol and PEITC has been shown to inhibit cell adhesion and until fibronectin 
expression. Therefore, FN1 was characterized. However, there were no significant 
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Figure 24 Integrin and FN1 gene changes in LNCaP xenografts in athymic nude mice.  following treatment with 
I3C. Changes in mRNA expression of integrin and FN1 genes were assessed in LNCaP prostate cancer cell 
xenografts in athymic nude mice provided dietary administered I3C. Real-time PCR analysis of A) ITGA2, B) 
ITGA5, C) ITGA6, D) ITGB1, and E) FN1 was performed as described in the Materials and Methods section. 
Values are reported as means ± SE. (*) represents significant differences between control and treatment diets at p 
< 0.05. 
Discussion 
In the present study, we demonstrated that I3C is capable of inhibiting tumor 
growth in an athymic mouse model. Key findings from this study revealed a 
significant reduction in tumor formation and growth, and altered expression patterns 
of genes interconnected with adhesion and xenobiotics defense pathways within the 
tumor and liver of mice fed diets containing 1 µmol I3C/g diet.  
Beneficial effects of cruciferous vegetable intake against prostate cancer have 
been demonstrated in previous studies (Aggarwal & Ichikawa, 2005; Souli et al., 
2008). However, the exact regulatory mechanisms in which I3C renders its cancer-
reducing effects have not been resolved under physiological conditions. To elucidate 
these mechanisms, physiologically relevant of I3C dosage was administered to 
animals in an amount up to 2.98 mg/ kg human body weight/ day. We did not find 
any major differences food consumption and body weight in animals fed control and 
I3C-containing diets. Despite the limited differences in phytochemical composition, 
significantly lower tumor burden, in terms of volume and formation were observed in 
the I3C-treated animals over time. Based on the findings of our studies, I3C may be a 
component within cruciferous vegetables that can be contributed to the prevention or 
regression of prostate cancer. The specific components attributed to prostate cancer 
regression are not known. Thus, future studies are of interest to uncover the 
associations between specific derivatives of indole-3-carbinol and tumor progression.   
Understanding possible gene-response relationships between cytochrome 
P450 enzymes and natural compounds and the resulting therapeutic efficacy is of 




increased expression of members of the 1, 2, and 3 families in the human CYP 
superfamily following exposure to I3C and its metabolites within xenograft models 
(Bjeldanes et al., 1991; Crowell, Page, Levine, Tomlinson, & Hebert, 2006; Leibelt, 
Hedstrom, Fischer, Pereira, & Williams, 2003). Therefore tissue-specific effects on 
key phase 1 xenobiotic metabolizing enzymes are of considerable interest. In line 
with the previously mentioned studies, our results indicate that dietary administration 
of I3C can upregulate xenobiotic pathways within the livers of human prostate cancer 
xenograft mouse model. Importantly, the diets in our study were ad libitum, at 
relatively low doses, and caused significantly increased expression of CYP enzymes 
compared with diet used in previous studies at much higher concentrations. Thus, 
xenobiotic metabolism regulation can be achieved with low I3C concentrations 
available through the diet. 
Our third major finding was the reduced expression of integrin genes 
following treatment with I3C. Previous studies suggest that increased integrin 
expression is a hallmark of cancer progression as related to the dysregulation of the 
extracellular matrix and invasion into other regions of the affected tissue or to 
different organs (Fornaro et al., 2001; Goel et al., 2008). Modulating integrins –A6 
and -B1 gene expression led to a decrease in prostate cancer tumor growth (Goel et 
al., 2005; King et al., 2008). Moreover, our study demonstrated that I3C may 
specifically regulate integrin genes. When tested against a panel of integrin genes 
under in vivo conditions, only ITGB1 was significantly downregulated. These results 
are unique in comparison to expression patterns against the same panel following I3C 
treatment in a LNCaP cell model. Under in vitro conditions, changes in cell adhesion 
may be an outcome of diminished ITGA6 expression. Results may indicate a 
compensatory role of integrins under in vivo conditions. Therefore, the reduced 
integrin expression observed following treatment with I3C may reflect a long-term 
protective adaptation that counteracts deregulated growth in prostate cancer.  
The factors mediating the changes in xenobiotic metabolism and integrin expression 
are unclear. But, indole-3-carbinol is an ideal candidate, which can drive diet-induced 
regulation of xenobiotic metabolism and cellular progression, including Cyp1a1, -




Previous studies have linked administration of I3C with the modulation of 
androgen responsive, proliferation, cell cycle regulation, inflammation, and monocyte 
attraction pathways. Therefore, inflammation surrounding the tumor site, for 
example, was investigated. Monocyte attraction to human prostate cells is responsible 
for the increased presence monocyte-derived macrophages and subsequent secretion 
of proinflammatory cytokines such as IL-1β within the tumor microenvironment.  
Previous studies have demonstrated the distinct ability of I3C to reduce monocyte 
attraction (E. K. Kim et al., 2013). However, results from this study did not uncover 
significant changes in IL-1β gene expression or protein levels under in vivo 
conditions. Differences from our study and the previously mentioned in vitro study 
include compound concentration amongst other factors. Interestingly, in light of the 
observed differences in tumor sizes following I3C exposure, tumor tissue assessed in 
our study did not exhibit any significant changes within the remaining pathways such 
as those that are androgen-responsive. Therefore, a more sensitive method to study 
the effects of I3C on human prostate cancer may be needed to reveal an association. 
This also suggests that other factors are linked to growth inhibition presented within 
tumors of animals fed I3C. Conversely, possible differences may be observed if 
interim samples are collected. 
Importantly, our study has, to the best of our knowledge, the lowest exposure 
of I3C in which effects of dietary interventions on human prostate cancer regression 
has been reported. We consider this a major strength since dietary recommendations 
are given on a long-term basis. Recent data proposed that I3C derivatives, instead of 
the parent compound, are responsible for chemopreventive results as previously 
thought. Future studies using I3C derivatives are needed in order to estimate the 
direction of Phase 1 xenobiotic metabolizing enzymes and integrins in vivo after 
dietary interventions.  
Conclusion 
In summary, we found low doses of I3C to significantly inhibit tumor growth 
in animals weeks after inoculation of LNCaP, human prostate cancer cells. 




mechanisms and increased xenobiotic metabolisms. Our study demonstrated 
potentially chemopreventive effects of diet-derived indole-3-carbinol by regulating 
defense responses in multiple organ systems. Our study supports previous findings 
demonstrating beneficial effects of I3C under in vitro conditions while highlighting 
sensitivities found among various animal strains. Moreover, testing should be done to 
identify novel alterations in endpoint markers leading to the observed decreased in 
tumor growth. The mechanistic effects of I3C along integrin-related pathways require 





Chapter 5: Summary and Significance 
 
Based on the conclusions of the three studies presented in this work, several 
future directions arise.  
 
1. Influence of mouse strains on chemopreventive effectiveness of indole-3-carbinol 
 
The second aim of our study was to assess the biological efficacy of I3C in a 
mouse model commonly used to assess prostate cancer. Genetic variation, for 
example, may affect the potency and effectiveness of biological compounds. 
Therefore, future work should be done to molecularly analyze and elucidate 
mechanisms of novel targets involved in the manifestation of prostate cancer. This 
would be to identify beneficial effects of indole-3-carbinol on a variety of mouse 
strains used as prostate cancer tumorigenic models. Understanding the effects on I3C 
on these mouse strains may provide insight on the influence of genetic variation on 
the sensitivity of this compound and its derivatives, more defined no effect levels 
(NOELs), optimal chemopreventive levels, and upper limits (ULs) and divulge the 
potential impact of its effectiveness as a chemopreventive agent on prostate cancer.  
 
2. Direct measures of cruciferous vegetable-derived compounds within xenograft 
models 
 
 The third aim of our study determined that indole-3-carbinol possesses 
chemopreventive effects on prostate cancer when consumed through the diet. 
Previous studies have shown a positive correlation between the amount of I3C 
administrated through the diet, compound metabolism, and its retention within blood 
plasma and urine of mice (Anderton et al., 2004). Findings from the third study 
indicated that I3C significantly upregulated Phase 1 xenobiotic metabolizing 
enzymes. Therefore, it may be of interest to examine metabolic processes of indole-3-
carbinol and phenethyl isothiocyanate. An example would include directly assessing 
for changes in Phase 1 and 2 xenobiotic metabolizing enzymes within prostate tumor 
following treatment with dietary compounds. Because indole-3-carbinol and 
phenethyl isothiocyanate may be immediately metabolized upon oral consumption, 




model’s system and are found within the tumor microenvironment. Therefore, 
following consumption of I3C or PEITC, derivatives inducing Phase 1 xenobiotic 
metabolizing enzymes may differ from the derivatives responsible for inciting 
enzyme expression with the tumors. Potential of these results may not only be 
beneficial to the health status of the general population but also has an agriculture 
incentive. This research could aid researchers in developing optimal conditions that 
impact the nutritional quality and composition of cruciferous vegetables made 
available to the public.  
 
3. Synergistic effects of indole-3-carbinol and phenethyl isothiocyanate 
 
Results from our study determined that PEITC differentially affects prostate 
tumors and its surrounding microenvironment than I3C on an androgen-dependent 
cell line. Future work may further profile the role of macrophage presence or examine 
the synergistic effects of I3C and PEITC under in vitro and in vivo conditions. 
Moreover, prostate tumors are composed of androgen-dependent and androgen-
independent variations. To our knowledge, there are no studies examining the role of 
PEITC and I3C in the athymic mouse model used in our study. Therefore, future 
work may also explore the effects of simultaneous exposure to PEITC and I3C on 






7 Hallmarks of Cancer  
There are several key steps in the transition from normal to cancerous 
epithelial cell growth: initiation, promotion, progression, and metastasis. The 
initiation phase is marked by the metabolism of cancer initiators such as carcinogens 
by xenobiotic metabolizing enzymes with the host system. If metabolized, the active 
initiators bind directly to DNA causing irreversible mutations that carry into daughter 
cells. The promotion phase is marked by abnormal cell growth as a result of cancer 
promoters and the production of daughter cells containing the same mutated genome. 
However, unlike the cancer initiators, promoters do not bind directly DNA or 
macromolecules within the cell. Instead, these promoter bind as ligands onto 
receptors on the cell surface in order to affect intracellular pathways that lead to 
increased cell proliferation. Moreover, it is in this phase where the promoted cells are 
recognized as benign tumors as they have slow growth patterns and adhesion 
properties with neighboring cells without invasion or metastasis. This phase is a 
critical point for dietary interventions (Surh, 2003). The third phase is progression, 
which is a stepwise transformation from benign tumor to malignant neoplasia. 
Characteristics of these progressive cancer cells are rapid cell growth, aggressive, 
invasive, and metastatic. Metastasis is the fourth phase and it is marked migration to 
secondary locations (other location in the organ or to other organs). Metastasis is 
accompanied by aggression. Characteristics of metastatic cells include loss of 








The prostate is the largest accessory sex gland in males. Located at the base of 
the bladder, a typical prostate gland may weigh approximately 50 grams and produces 
a secretion that aids in the production of semen and disintegration of cervical mucus. 
Of the accessory sex glands, the prostate is the most susceptible to cancer, despite all 
the sex glands having similar embryonic origination. There are four main regions 
within the prostate gland, which includes the central, transitional, periuretal, and 
peripheral zones. The epithelium within the peripheral zone is regulated by active 
androgen, dihydrotestosterone (DHT). Each of the four areas are susceptible to 
prostate cancer development. However, the region most affected by prostate cancer is 
the peripheral zone, which is the most susceptible to inflammation due to containing 
70% of the prostate’s glandular tissue. 
Prostate Cancer 
 
Prostate cancer development is complex. General consensus of the literature 
suggests that cancer begins from a single androgen sensitive cell and expands clonally 
acquiring mutations. The mutation then manifests into genetic alterations such as 
those leading to androgen independence. Low-growth fraction refers to the proportion 




have a low growth fraction, which makes them relatively resistant to many of the 
traditional chemotherapeutic agents that are targeted at dividing cells (L. W. K. 
Chung, Isaacs, & Simons, 2001).  
Two characteristics that make prostate cancer unique is its early stage: 
androgen sensitivity and relatively low growth fraction. Effective treatment for 
prostate cancer remains unknown. Androgen deprivation, through surgical or 
chemical castration, has been used for nearly 80 years for the regulation of prostate 
cancer. Results of this method have led to significant tumor regression by induction 
of programmed cell death in androgen responsive prostate cancer cells. However, by 
the time of clinical detection, these tumors may have heterogeneous populations 
ranging from androgen dependent to androgen sensitive and independent cells. 
Therefore, androgen ablation may result in significant androgen-dependent cell death, 
but it eventually selects for androgen sensitive and independent cancer cells (L. W. K. 
Chung et al., 2001). 
The specific targeting of cancer cells has become a unifying theme supporting 
the development of novel therapeutic modes (Peng et al., 2008). Often, the targeting 
molecules are antibodies, or peptides, which bind to cell-surface membrane proteins 
that are specifically-, or over-expressed on malignant cells but not expressed on 
healthy cells. These innovative targeted therapeutic and diagnostic methods promise 
to increase both the specificity and efficacy of prostate tumor diagnosis and treatment 
while reducing the side effects (Adair, Parette, Altinoğlu, & Kester, 2010; Afnan & 




dietary intervention as a preventive measure is ideal due its generally high availability 
and low side effects.  
Sex Hormone 
Role of Androgen in Prostate Cancer Development 
Androgens play a multifaceted role in the development and maintenance of 
healthy prostate functioning as well as the progression to prostate cancer. However, 
the exact role androgens have in the transition from normal to cancerous conditions 
remains unresolved.  
The “Androgen Hypothesis” published by Charles Huggins in 1941, 
determined that castration caused PCa regression in men with metastatic disease. 
Huggins concluded that testosterone proportionately activates PCa and enhances 
growth rate. More recent research suggests that high levels on testosterone may only 
affect long term risk (Muller et al., 2012). The Saturation Model, proposed by Adam 
Morgentaler, suggests that PCa cells utilize a certain level of androgens that supports 
optimal growth. The presence of androgen has a limited ability to stimulate benign or 
malignant prostate tissue, implicating cellular self-sufficiency, not the level of 
androgen, as the main drive of cancer progression (Morgentaler, 2012).  However, 
there’s overwhelming scientific evidence supporting the presence of androgen in the 
promotion and progression of prostate cancer. 
Testicular synthesis of testosterone, prominent male sex steroid hormone, 
accounts for approximately 90% of the dihydrotestosterone (DHT), an active form of 
testosterone, found in the prostate. The remaining testosterone is secreted peripherally 




preferentially binds to the androgen receptor (AR) at an approximately 10x higher 
affinity than testosterone(Drug Management of Prostate Cancer, 2010). 
The AR is a member of the steroid hormone superfamily, which includes 
estrogen, progesterone, and glucocorticoid receptors (Beato, 1989; Beato, Chalepakis, 
Schauer, & Slater, 1989; R. M. Evans, 1988). The AR serves as a ligand-binding 
transcription factor. These receptors exists in the nucleus and consists of three 
domains: 1) a carboxy-terminal hormone-binding domain; 2) an amino-terminal 
transactivation domain, and a 3) DNA-binding domain located between domains 1 
and 2 (Beato et al., 1989; Jenster et al., 1991). After testosterone or DHT binds to the 
AR, an hormone binding domain, the receptor becomes phosphorylated, translocates 
into the nucleus, to subsequently, bind to AREs as dimers. Essentially, the genes 
whose expression is stimulated by androgen are flanked by specific DNA sequences, 
called androgen response elements (AREs), which are recognized by the DNA-
binding domain of the AR (Jenster et al., 1991). Thus, stimulating transcription of 
androgen-inducible genes and ultimately, protein synthesis leading to the observed 
changes in cell proliferation, survival, and differentiation (Drug Management of 
Prostate Cancer, 2010; Jenster et al., 1991; Riegman, Vlietstra, van der Korput, 
Brinkmann, & Trapman, 1991). 
Ultimately, the androgen signaling pathway plays a critical role in the 
progression of prostate cancer, especially in early stages. Elevation of testosterone 
may not be a sole determinant in the diagnosis of cancer due to the overall complexity 
of prostate cell development and heterogeneity within the tumor and surrounding 




Influence of Estrogen on Prostate Cancer Development 
Androgen in prostate cancer has specificity for estrogen in addition to 
androgen. Low levels of estrogen have been found in men. More importantly, I3C has 
been shown to modulate estrogen receptor amongst other nuclear transcription factors 
(Y. S. Kim & Milner, 2005).  
Androgen Responsive Biomarkers: PSA and NKX3.1 
Androgen Responsive Biomarkers: PSA and NKX3.1 
Prostate specific antigen (PSA), also known as kallikrein-3 (KLK3), is a serine 
protease secreted by prostate gland epithelial cells. The gene encoding PSA is a 
member of the kallikrein family and its expression is regulated by the presence of 
androgens. Prostate specific antigen is a glycoprotein with a molecular weight of 29 
kDa and is commonly used as a marker for human prostate epithelial and prostate 
carcinoma cells growth (Papsidero et al., 1981; M. C. Wang et al., 1981).  
Practical Approaches for PSA. PSA functions as an essential component for seminal 
fluid. Biopsies are recommended if abnormal PSA levels are found. United States 
Preventive Services Task Force considers PSA as gold standard biomarker but does 
not recommend PSA screening as a sole indicator of prostate cancer since elevated 
expression levels may not correlate with PCa risk (Ablin, 2012; Catalona, 2012). 
Moreover, results from a European Randomized Study of Screening for Prostate 
Cancer imply that there is around a 75% negative biopsy rate using PSA as a 
diagnostic marker (A. Gupta et al., 2010; Studer & Collette, 2010). These results 




with subsequently confirmed malignancy due to small and inconspicuous lesions 
(Rabbani, Stroumbakis, Kava, Cookson, & Fair, 1998).  
In a Physician’s Health Study, mRNA signatures were developed from 
patients with a Gleason score of 7, the most common grade. Conclusions from this 
study implicated the use of this signature to further estimate the risk of lethal prostate 
cancer and guiding therapy decisions to improve outcomes and reduce overtreatment 
(Penney, Sinnott, et al., 2011). Mixed findings from a clinical study conducted by 
Muller et al, suggests that variation in testosterone levels at the time of baseline 
readings affects PCa predictability. In this study, higher testosterone was associated 
with higher PCa detection but unrelated to PCa risk (Muller et al., 2012).  
PSA remains present in prostate cancer cells after they become malignant. 
However, the role of PSA as sensitivity to androgenic growth hormones decreases 
and growth becomes independent of hormones remains unclear. 
Immunohistochemical analysis of PSA reveals weak staining due to the disruption of 
their normal functioning (Papsidero et al., 1981; M. C. Wang et al., 1981). Thus, 
individual prostate cancer cells may produce less PSA than healthy cells. But the 
raised serum levels in individuals with prostate cancer may be due to increased cell 
numbers not necessarily individual activity. However, in most cases of prostate 
cancer, the cells remain positive for the antigen, which can therefore be used to 
identify metastasis (Manual of Diagnostic Cytology, 2003). Since some high-grade 
prostate cancers may be entirely negative for PSA, however, histological analysis to 
identify such cases usually uses PSA in combination with other antibodies, such as 




NKX3.1 is a member of a large family of homeodomain transcription factors 
and helps regulate the production of secretory proteins (Bhatia-Gaur et al., 1999; He 
et al., 1997; Prescott, Blok, & Tindall, 1998). NKX3.1 can be found in high levels in 
the prostate and various organs including salivary glands, the kidney, and portions of 
the central nervous system (Sciavolino et al., 1997; M. Tanaka et al., 2000). NKX3.1 
may be expressed in an androgen-dependent manner (Erbaykent-Tepedelen, Karamil, 
Gonen-Korkmaz, & Korkmaz, 2014; He et al., 1997; Prescott et al., 1998). Although 
NKX3.1 may not be essential, the loss of function of NKX3.1 might be associated 
with the development of prostate cancer. NKX3.1 is localized to chromosome 8p21 
and its protein has a molecular weight of 26 kDa in humans (Voeller et al., 1997). 
Loss of heterogeneity (LOH) at this locus occurs in prostate cancer and is associated 
with more aggressive or invasive tumors, suggesting the presence of a tumor 
suppressor gene in the 8p21-8p22 interval (Bova et al., 1993; Kagan et al., 1995; 
MacGrogan et al., 1994; Suzuki et al., 1995). Thus, it is unclear whether this protein 
is a bona fide tumor suppressor gene in human prostate cancer, however, has been 
shown to elicit a DNA damage response (Erbaykent-Tepedelen et al., 2014; Voeller et 
al., 1997). However, haploinsufficiency occurs when a diploid organism may only 
have one functional copy of an allele due to the second copy being inactivated 
(possibly by a mutation). Findings from experimental mice studies have shown that a 
phenotypic consequence of loss of one allele of NKX3.1 may significantly increase 
the likelihood of haploinsufficiency of this gene in human tumors, which results in an 
inclination towards tumor formation or progression (Bhatia-Gaur et al., 1999; Thomas 




Progression of Prostate Cancer 
 
Androgen dependent prostate cancer cells tend to be nonaggressive and 
remain within original tumor site. Androgen depletion from these cells will mostly 
lead to regression of growth leading to apoptosis.  However, cancerous cells may 
evade cell death by going into a resting state and survive without cycling into the G0 
phase (Bostwick et al., 2004). The tumor cells accumulate more mutations and lead to 
a more aggressive state, thus, increasing the likelihood of invasion and metastasis into 
other regions. This may be another reason how cells metastasize into bone marrow or 
other sites following clinical treatment (Hoimes & Kelly, 2010). However, the 
biological characteristics of androgen-dependent prostate cancer cells, especially in 
regards to their ability to adapt following clinical depletion of androgen, are not fully 
understood making it difficult to elucidate a safe, effective cure for prostate cancer. 
Malignancies of prostate cancer is fairly common and affects nearly 1 in 11 males 
(Landis et al, 1998 and Pisani et all, 1999). Prostate cancer preferentially metastasizes 
in the bone and has been report in approximately 75% of patients with advanced stage 
prostate cancer (Coleman, 1997). In general, these metastases are sclerotic, rigid and 
highly resistant to treatment (Bostwick et al., 2004). 
Although difficult to determine how prostate cancer cells depend on 
androgen-mediated signaling for survival. In order to shift from androgen-dependent 
to androgen-independent growth, cells must adapt their survival mechanisms, leading 
to more resistant and aggressive state (Fowler, Lau, Ghosh, Mills, & Mounzer, 1988; 




1989; Matuo et al., 1987; Matuo et al., 1988; Sitaras, Sariban, Bravo, Pantazis, & 
Antoniades, 1988). 
Several Aspects that Differentiate Cancer from Normal Cell Development 
 
There are several aspects that contribute to the transition of normal cells into 
cancerous cells and further enable the prostate cancer cells to transition from benign 
through malignant, androgen-independent conditions. The hallmarks of cancer 
include: self sufficiency in growth signals; insensitivity to anti growth signals; 
evading apoptosis; limitless reproductive potential; sustained angiogenesis; tissue 
invasion; and metastasis. 
Loss of Density-dependent Cell Proliferation and Deregulation of Apoptosis 
 
Normal cells are able to maintain a balance between proliferation and 
apoptosis signals. If mutations are allowed to evade checkpoints and repair 
mechanisms, the balance shifts favoring proliferation in preneoplastic or neoplastic 
growth states. In tumors, proliferative signaling pathways dominate paired with 
impaired apoptotic signaling, which differentiate them from their normal 
counterparts. KI67 and BCL2 were ideal biomarkers for proliferation and apoptosis, 
respectively. 
Apoptosis is an active, inherent, programmed cell death that may be initiated 
by a multitude of environmental stimuli. The idea of apoptosis was introduced by J. 




apoptosis was noted to play both a complementary and opposing role to mitosis in the 
regulation of animal cell population. During normal functioning, cellular reproduction 
is homeostatic to cellular death. While in cases of toxicity, apoptosis may be 
considered the endpoint of toxic injury, which are comprised in various forms that are 
specific to causes and functions.  
Apoptosis differs from necrosis, which involves violent environmental 
perturbation leading to the rapid incapacitation of major cell functions such as gene 
expression, ATP synthesis, and membrane potential. 
Biomarkers: KI67 and BCL2 
 
Ki67 is a nuclear protein encoded by marker of proliferation (MKI67). It is 
considered an indicator for cell proliferation and assesses for the growth fraction of a 
cell population. Ki67 expression is uniquely robust in its presence in all cell cycle 
phases except for G0. Grading of prostate cancer does not consider the proliferation 
rate of cells so Ki67 can improve predictions of prostate cancer outcome based on 
standard factors alone in men treated conservatively or radically (G. Fisher et al., 
2013; Jhavar et al., 2009). Moreover, KI67 protein expression directly reflects a 
certain physiological state of the cell, despite being little consensus in the choice of 
Ki67 cutoff points (G. Fisher et al., 2013). 
B-cell lymphoma 2 (BCL2), is a part of a family of cytoplasmic proteins that 
regulate apoptosis through the induction or inhibition of apoptotic factors. The BCL-2 
family members can form homo- and heterodimers through the BH3 domains. BCL2 




apoptotic activity of BAX. Thus, the relative levels of pro-survival and pro-apoptosis 
BCL-2 family proteins determine cell survival or apoptosis, as in the case of cancer 
cells high expression BCL2 versus normal cells that highly express BAX or BAK. 
High expression of BCL2 has been implicated in advanced prostate cancer (Catz & 
Johnson, 2003). BAK and BAX often form homo- or heterodimers in the presence of 
apoptotic signals. This homodimer promotes the opening of a channel and promotes 
translocation of cytochrome c from mitochondria to the cytoplasm. If BAK or BAX 
dimers are neutralizes by the binding of BCL2, the channel cannot open and 
cytochrome c cannot translocate, which may inhibit the completion of apoptosis. 
Overexpression of survival proteins such as BCL2 has been implicated in prostate 
cancer progression. Elevated levels of BCL2 have frequently been associated with 
aggressive tumorigenesis and chemoresistance (Catz & Johnson, 2003; McDonnell et 
al., 1992). BCL2 and other oncogenes, through the products they encode, may be 
regulated by protein phosphorylation by protein kinases with tyrosine and threonine, 
as the substrate amino acids. Since BCL2 is overexpressed in prostate cancer cell 
lines, phytochemical treatment assists with maintaining BCL2/BAX balance by 
lowering BCL2 expression to allow apoptosis to occur in those lines. 
Sustained Growth 
 
Sustained growth is another hallmark characteristic of cancer progression. As 
prostate cancer becomes more resist, its ability to override and manipulate 
proliferation and survival pathways becomes more complex. Activations of these 




and survival through signal transduction pathways. One such survival pathway is 
through PI3K/AKT.   
 
IGF and EGF are potent mitogens known to influence proliferation and survival 
cascades.  
Self-Regulation of Growth Factors 
 
Impaired growth factor functionality and evasion of stop signals are hallmarks 
in uncontrolled tumor growth. Growth factors, such as epidermal growth factors 
(EGFs), vascular endothelial growth factors (VEGFs), keratinocyte growth factor 
(KGF), and platelet-derived growth factors (PDGF) are small molecules that have 
shown to be an integral part in the growth and development of cancer. 
Epidemiological studies have highlighted the importance of and provided evidence 
that has correlated increases in insulin-like growth factor (IGF-1) with an increased, 
associated risk for prostate cancer (Russell, Bennett, & Stricker, 1998). 
There are two general types of growth factor signaling pathways. In the 
autocrine stimulatory pathway, cells are responsible for generating the growth factor 
and the ligand. On the other hand, the paracrine stimulatory pathway is one in which 
surrounding cells provide crucial growth factors to the cancer cell. Both pathways 
may to contribute to the progression of prostate cancer. For instance, in a study 
conducted by Scher et al, prostate cancer cells were shown to express the EGF 
receptor and its cognate ligand, transforming growth receptor factor alpha (Scher et 




progression of prostate cancer. Evidence of possible paracrine stimulation in prostate 
cancer progression comes from the observation both in the gland and at metastatic 
sites (Barrack, 1997). 
The expression of IGF, EGF, and other peptide growth factors and their 
receptors may be regulated by androgen (Oosterhoff, Grootegoed, & Blok, 2005). 
The activation of specific growth factor pathways in vitro can enhance AR activity, 
even in the absence of androgens. These observations are critical in the connection of 
AR functionality to pathways involved in cancer progression. In a study conducted by 
Putz et al suggests that EGF, or IGF-1 stimulated cell growth and PSA secretion in 
DU145 cells that may be independent of androgen (Putz et al., 1999).  
Androgen-dependent production of cell survival factors may contribute to 
repressed apoptosis in prostate cancer. Such factors include the production of secreted 
peptide survival factors like IGFs, platelet-derived growth factors (PDGF), and 
vascular endothelial growth factor (VEGF). For example, IGF-1 may bind and 
dimerize its transmembrane receptor (IGF-1R). Once dimerized, each monomer 
transphosphorylates the opposing monomer on specific tyrosine residues. This 
tyrosine transautophosphorylation functions to recruit intracellular signaling proteins 
to bind via their src homology 2 domains to specific phosphorylated tyrosines in the 
ligand-occupied dimeric receptor complex (Porter & Vaillancourt, 1998). This 
autophosphorylation initiates three major kinase-dependent signaling cascades. These 
include: (a) the ras/raf/Mek/srk cascade, (b) the phospholipase C(gamma)/ 
diacylglycerol/ inositol triphosphate (IP3)/ protein kinase C cascade, and (c) the 




B (PKB aka AKT) (Kantoff, Carroll, & D'Amico, 2002). PI3K/Akt pathway is 
implicated in the regulation of prostate cell survival. 
This PI3K/Akt signaling pathway begins with the binding of growth factors 
such as IGF-1 to the IGF-1 receptor (IGF-1R). Ligand binding results in receptor 
activation and recruitment of the PI3K complex to the plasma membrane. PI3K 
phosphorylates a specific type of lipid found in the plasma membrane, which 
generates a lipid product known as phosphoinositide-3, 4,5-triphosphate (PI-3,4,5-
P3). PI-3,4,5-P3 is induced on growth stimulation by activating survival cascades 
(Kantoff et al., 2002). When present, PI-3,4,5-P3 recruits and activates a second 
kinase, known as Akt. There are three Akt kinases (Akt-1, -2, and -3), which are 
responsible for phosphorylating various downstream targets to sufficiently inhibit 
apoptosis and promote cell proliferation. Activation of this pathway has been 
associated in the regulation of cell adhesion and cell motility (Kantoff et al., 2002).  
Numerous human studies have found increasing levels of plasma IGF-1 to be 
associated with the diagnosis of prostate cancer (Chen et al., 2009). In a population- 
based case control study conducted by Wolk et al, serum IGF-1 levels were positively 
associated with prostate cancer risk (Wolk et al., 1998). Furthermore, in the 
prospective Physicians’ Healthy Study conducted by Penney et al, IGF-1 was also 
considered a strong risk factor for the development of prostate cancer (Penney, 
Sinnott, et al., 2011). Men in the highest quartile of plasma IGF-1 level were found to 
have a relatively higher risk of prostate cancer and elevated risk of cancer-related 
death when compared to men in the lower quartile. Conclusions from this study 




IGF-1’s roles in prostate cancer was proposed nearly two decades ago, more recent 
review of studies have shown the role of IGF-1 in androgen receptor regulation via 
PI3K/AKT pathway at low androgenic concentrations (Papatsoris, Karamouzis, & 
Papavassiliou, 2005; Pollak, Schernhammer, & Hankinson, 2004). Findings from 
these reviews suggest that IGF-1 expression is regulated by androgens through AREs 
in the IGF-1 promoter regions and the IGF-1 signaling pathway through the 
regulation of IGF-binding protein (IGFBP) expression.  
Moreover, reduction of freely circulating IGF-1 in prostate cancer may also be 
associated with the reduced expression of its receptor. Wang et al demonstrated that 
treatment of I3C and DIM in LNCaP cells significantly reduced IGF-1 receptor 
expression as a means to inhibit IGF-promoted cell growth (T. T. Wang et al., 2012). 
Findings from this study warrant further exploration into the effects of I3C and 
PEITC on IGF and EGF growth modulation in in vivo systems 
Biomarker: IGFBP3 
 
Insulin-like binding protein 3 (IGFBP3) is a member of the IGFBP family. 
This protein has a high affinity and specificity to IGF-1, and is responsible for 
extending its serum half-life, circulating bioavailability, and modulating IGFs 
biological actions on target cells. Additionally, IGFBP3 may contribute to IGF-
independent functions within the cells by inducing apoptosis or inhibiting cell growth.  
IGFBP3 plays a critical role in the progression of prostate cancer (Gu et al., 
2010). Proper regulation of IGFBP3 is accounts for a constant concentration of IGF-




reduces its affinity to bind IGF-1 and increases amount of circulating IGF-1 (P. 
Cohen, Peehl, Graves, & Rosenfeld, 1994; Gu et al., 2010; Penney, Schumacher, et 
al., 2011). Therefore, dysregulation of hormones such as androgens play a significant 
role in modulating changes in cell growth during the early stages of prostate cancer.  
Significantly, IGF-1 and IGFBP3 are regulated by dietary modification. I3C 
and PEITC have been shown in increase the expression of IGFBP3 gene, which may 
reduce bioavailability of circulating growth factors (R. W. Li et al., 2013). As one of 
the most abundant circulating carrier proteins, accounting for approximately 80% of 
all IGF-1 binding in human systems, IGFBP3 is considered an ideal prognostic 
biomarker and important antitumor agent targeting the down regulation of prostate 
cancer. 
Cell Cycle Regulation 
 
The cell cycle is regulated by networks of interacting proteins that receive 
signals from extra- or intracellular sources and integrate these responses into 
stimulatory and inhibitory pathways that decide the cell’s fate. The cell cycle consist 
of 4 phases: G0, G1, S, G2 and mitosis. Normal cells reach density-dependent 
inhibition and become quiescent, arrested in G0 phase. G1 is the first gap phase and is 
affected by growth factors, inhibiting factors, and nutrient supply. In this phase, the 
cell may move to the S phase, arrest in G1 phase, or move into G0 phase. Moving into 
the S phase, DNA synthesis, is a critical point for the cells. In this phase, DNA 
damage is detected and fixed via repair systems. Epithelial cells may override G0 




for error, which could contribute to cancer recurrence. Cancer cells overriding G1/M 
and G2/M checkpoints. CDKN1α and CDKN1β play an important role in the 
decision-making machinery in R-point process and have been chosen as cell cycle 
biomarkers. 
Biomarkers: CDKN1α and CDKN1β 
 
Cyclin-dependent kinase (CDK) such as CDK1 plays an important role in the 
regulation of procession into S phase. Cyclins complex with CDKs to activate CDKs’ 
catalytic activity, which is a process mediated by extracellular signals and other 
mitogens. Cyclin D kinase inhibitors are another molecular target to prevent cell 
cycle progression and treat cancer. In prostate cancer, CDKN1α and -β have been 
shown to play a prominent role in cell cycle regulation by binding and inhibiting 
cyclins. This two inhibitors act as tumor suppressor genes to support cell growth 
arrest and progression at G1 and S phases. 
In prostate cancer, Cyclin-D kinase Inhibitor 1-α (CDKN1α) is also known as 
P21, without inducing p53 and cyclin-D kinase Inhibitor 1- β (CDKN1β), also known 
as P27, are found at reduced levels.  In a study conducted by Wang et al, I3C and its 
metabolite, DIM significantly induced cyclin inhibitors at concentrations ≥ 25 µmol/L 
media (T. T. Wang et al., 2012). 
Decreased Regulation by Cell-Cell and Cell-Matrix Interactions 
 
E-caderin is a principle adhesion molecule in epithelial cells. The loss of E-




mesenchymal transition (EMT) has had a crucial role in the regulation of tissue 
fibrosis and cancer pathogenicity. Under cancerous conditions, prostate epithelial 
cells may acquire mutations enabling them to loss differentiated adhesion properties 
in order to migrate and invade through the activation of EMT-related biological 
pathways. Moreover, inducible changes observed in EMT may be perturbed by the 
presence of androgens (E. K. Kim et al., 2013). 
Insensitivity to Contact and Migration  
 
Integrins, as cell adhesion receptors, may play a critical role in cell migration- 
a critical step in cancer progression. Epithelial cells that normally would not migrate 
may gain the ability to metastasize to other regions. This is also a critical step in 
differentiating benign from malignant cancer.  The mechanism involved in cell 
motility is complicated and involves complex interactions between the cell and the 
extracellular matrix (ECM).  
The interaction of integrins with the extracellular matrix is complicated. 
Integrins utilize an outside-in or inside-out signaling approach to regulate ligand 
binding and adhesion (Takada et al., 2007).The ligands for integrins are numerous 
and can be extracellular matrix ligands, cell-surface ligands, and soluble ligands. The 
ability of integrins to move relies on their ability to form transmembrane protein 
complexes on the surface of the cell. This is accomplished by forming alpha-beta 
heterodimers. Integrins have unique specificities, which allow them to be categorized 
into laminin-, collagen-, fibronectin-, leukocyte- binding integrins, with some overlap 




(ICAMs), which are present on inflamed endothelial layers. These molecules promote 
ligand binding, which help integrins communicate.  
Biomarkers: Integrin and FN1 
 
Integrins are dysregulated in prostate cancer. ITGA2, -5, -6 and ITGB1 are 
aberrantly upregulated in human PCa and TRAMP (Goel et al., 2005; Goel et al., 
2008).  –B1 associates with many alpha subunits and may predominantly associate 
with –A2, -A5, and –A6 subunits to form heterodimeric complexes (Alam et al., 2007; 
Bonkhoff et al., 1993; Fornaro et al., 2001). –B1 is also very important in the 
regulation of cell growth and previous studies have shown that –B1 assists cell in 
anchorage-independent growth.  
Fibronectin 1 (FN1) is an extracellular matrix glycoprotein, with a molecular 
weight of 220 kDa. This protein binds to integrins and may be responsible for the 
promotion of cell adhesion, growth, migration, and differentiation. The up-regulation 
of –B1 and fibronectin ligand may promote prostate cancer cell progression (Goel et 
al., 2008). 
Integrins can bind to ECM glycoproteins including collagens, fibronectins, 
laminins, and cellular receptors  (VCAM-1 and ICAM) (Takada et al., 2007). ITGA2 
contains collagen and laminin receptors (Dickeson, Walsh, & Santoro, 1998). Integrin 
heterodimer, A2B1, may primarily contain collagen receptors (Ruggiero, Comte, 
Cabañas, & Garrone, 1996; M. A. Schwartz et al., 1995). Heterodimer, A5B1 is a 
major fibronectin receptors (van der Flier & Sonnenberg, 2001) and heterodimer, 




The use of dietary phytochemicals such as I3C and PEITC to regulate cell 
adhesion cell migration has been explored. Treatment with PEITC disrupts cell 
adhesion properties under in vitro and in vivo conditions. In a study conducted by 
Hudson et al, treatment with doses up to 5 µmol/L significantly inhibited cell plating 
efficiency and down-regulated integrin expression in androgen-sensitive LNCaP cell 
line (Hudson et al., 2012). Moreover, Li et al demonstrated that dietary administered 
treatment with 3 µmol PEITC/g diet to significantly alters integrin expression in a 
LNCaP xenograft study (R. W. Li et al., 2013) 
Properties that Affect Interactions with Other Tissue Components 
 
A cancer cell’s ability to micrometastasize depends on their ability to 
modulate and secrete angiogenic factors that may interact with the vascular 
endothelium and breakthrough the resistance of the endothelial-barrier. Controlling 
for factors that decrease the probability of micrometastasis has potentially high 
applications in nutrition-related cancer therapy and metastasis prevention. Due to the 
complexity of molecular mechanisms leading to micrometastasis, developing 
chemopreventive strategies to target prostate cancer utilizing dietary agents ideal but 
requires additional research.  
Biomarkers: VEG-F and PECAM 1 
Vascular endothelial growth factor (VEG-F) is expressed by a variety of 
tumor cells and infiltrating macrophages (Dvorak, 2002). Prostate cancer cells have 
been shown to make autocrine growth factors such as VEGF as well as its receptor. 




expression has been correlated with prostate cancer disease staging and prognosis 
(Ferrara, 2000). VEGF expressed by tumor cells or macrophages may directly 
stimulate endothelial cell proliferation and migration (Morgan, Forssmann, & 
Nakada, 2004).  
Platelet/ endothelial cell adhesion molecule (PECAM-1) is also known as CD-
31. Moreover, this gene is located on the surface of platelets, monocytes, neutrophils, 
and other T-cells as well as comprising a large proportion of the endothelial cell 
intercellular junctions. The most notable functions of PECAM-1 revolve around its 
role in regulating prostate cancer angiogenesis and integrin activation. In a clinical 
study conducted by Ding et al, PECAM-1 and VEGF were positively correlated with 
neoangiogenesis and tumor metastases in individuals with prostate cancer.  Of the 34 
cases, 44.12% were positive for VEGF mRNA expression, which as also inversely 
proportionate to the cancer stages I- IV (Ding, Li, Xu, Sun, & Tao, 2005). Moreover, 
in another clinical study conducted by Huss et al, VEGF and PECAM-1 were 
analyzed in TRAMP mouse model, with undergoes a distinct angiogenic switch that 
is consistent with the recruitment of new vasculature to lesions representative of PIN. 
Analysis of clinical samples within this study also validated the predictions of the 
TRAMP model, which may explain how anti-angiogenic dietary therapy may change 
the function of tumor progression (Huss, Hanrahan, Barrios, Simons, & Greenberg, 
2001). 
PEITC influences the expression rate of angiogenic factors in the early stages 




has significant attenuated the angiogenic potential in early stage, androgen-responsive 
human prostate cancer (Hudson et al., 2012). 
Chronic Inflammation 
 
Inflammatory cells, particularly macrophages, are heavily involved in the 
management of the tumor microenvironment, where they have been previously shown 
to influence the tumor metastasis and cell growth. However, the mechanisms 
involved in their cellular events are not fully understood (Morgan et al., 2004). 
In normal inflammation, macrophages are an integral part in the M2 
remodeling phase to help resolve a wound. However, different from normal 
environments where macrophages would disperse following wound repair, in a tumor 
microenvironment, they linger, remain in the M2 phase, and contribute to a state of 
chronic inflammation.  In the M2 phase, they react with tumor cells, fibroblasts, and 
epithelial cells to promote angiogenesis and fibrosis.  
Cytokine secretion from macrophages has a profound influence on tumor 
growth. Cytokines are soluble glycoproteins and low-molecular weight particles with 
multiple functions. However, they are mainly responsible for mediating intracellular 
interactions to regulate cell and tissue functions (Dunlop & Campbell, 2000). 
Cytokines contribute to the growth and spread of cancers by causing normal cells to 
produce additional cytokines that continue the malignant process (Dunlop & 
Campbell, 2000; Negus & Balkwill, 1996). 
Cancer preventive techniques seeking to destroy the crosstalk interference and 




dietary agents or components naturally found in the diet are ideal due to the ease of 
acquirement, low side effects, and are key preventive measures utilized by health 
professionals. 
Biomarkers of Inflammation 
 
Secretion of IL-1β, an autocrine-produced cytokine, promotes cancer cell 
growth and confers with aggressive resistance against traditional therapeutic 
measures in LNCaP, human prostate cancer cells. High levels of IL-1β may also be 
responsible for the induction of angiogenic factors such as VEGF from the tumor and 
stromal cells that promote tumor growth through increased vascularization of human 
prostate cancer cells.  Moreover, increased presence of IL-1 within the tumor 
microenvironment significantly enhances the expression of adhesion molecules in 
endothelial and malignant cells. This, in turn, facilitates malignant cell invasion, 
driving them into the circulatory system and promoting dissemination into distant 
tissues (Chirivi et al., 1996). 
Interleukin 1 receptor antagonist (IL1RN) is a member of the interleukin 1 
cytokine family that mediates the activity of IL-1 and IL-1-related immune and 
inflammatory responses. IL-1 receptor antagonist is encoded by the IL1RN gene in 
humans. Essentially, the IL-1 receptor binds IL-1(Apte & Voronov, 2008). However, 
IL1RA can also non-productively bind to the IL-1R, attenuating the effects of IL-1. 
Therefore, changes in IL1RN gene expression may be correlated with the inhibition 




regulation of IL1RN is ideal target for tumor growth reduction (Morgan et al., 2004; 
Rodríguez-Berriguete et al., 2013). 
IL-6 is a multifunctional glycoprotein that is secreted by various cells(Guo, 
Xu, Lu, Duan, & Zhang, 2012). However, under normal conditions, its secretion is 
tightly controlled and its expression is relatively low. The role of IL-6 in prostate 
cancer is unresolved. Elevated levels of IL-6 have been linked to disease progression 
and morbidity in clinical studies (Michalaki, Syrigos, Charles, & Waxman, 2004; Wei 
et al., 2003). However, in vitro experiments have shown that IL-6 may stimulate or 
inhibit cancer growth.  There are reports indicating that IL-6 may or may not be 
secreted in LNCaP cell line (T. D. Chung, Yu, Spiotto, Bartkowski, & Simons, 1999; 
P. C. Smith, Hobisch, Lin, Culig, & Keller, 2001). In general, studies indicate that 
elevated expressions levels play a critical role in prostate cancer development but 
understanding the role of IL-6 secreted by the prostate cancer cells and the role of 
exogenous IL-6 within the tumor microenvironment remains elusive. The pro-
angiogenic effects of IL-6 expressed by macrophages have been attributed to the 
stimulation of VEGF expression(Tartour et al., 1994; Wei et al., 2003).  
C-C Chemokine Ligand 2 (CCL2) is also known as monocyte chemoattractant 
protein (MCP-1), and has a significant role in perturbing prostate cancer progression. 
CCL2 presence within tumor cells initiates the activation of monocytes to 
macrophages by luring them to the surrounding inflamed microenvironment. Active 
binding of CCL2 to CCR2, a cognate ligand receptor, has been shown to stimulate 
prostate cancer development (Allavena, Sica, Solinas, Porta, & Mantovani, 2008). A 




behavior of androgen-dependent cell line. Results from the study also demonstrated 
I3C’s ability to significantly decrease monocyte infiltration in LNCaP cell model. 
These results are further confirmed by other studies denoting the presence of CCL2 in 
more advanced prostate cancer cells lines such as C4-2B, PC-3, and VCaP (E. K. Kim 
et al., 2013; T. H. Lin et al., 2013; Roca, Varsos, & Pienta, 2009). 
As another multifunctional cytokine, tumor necrosis factor-α (TNFα) plays a 
crucial role in the progression of cancer growth and metastasis. In a clinical study 
conducted by Michalaki et al, elevated TNFα serum levels with increased disease 
status. Serum levels for TNFα were higher in prostate cancer patients with metastatic 
disease and lower in those with localized disease (Michalaki et al., 2004). 
Macrophages (MΦ) within Tumors 
 
Macrophages are a diverse, heterogenous population that responds to 
environmental stimuli in order to maintain tissue homeostasis and remodeling under 
normal conditions. As inflammatory regulators, their protective feature can also 
promote disease progression by overstimulating inflammation and angiogenesis 
(Allavena et al., 2008; Condeelis & Pollard, 2006). Macrophages may infiltrate tumor 
tissues and promote all aspects of tumor initiation, growth, and development. 
Moreover, these inflammatory infiltrates are considered the dominant leukocyte 
population found within the microenvironment surrounding neoplastic tissue. 
Macrophages may differentiate from monocytes that are recruited into the tumor by 
chemokines and cytokines derived by tumors such as vascular-endothelial growth 




vascularized, hypoxic, and necrotic areas, promotes macrophage accumulation and 
further perturbs the tumor microenvironment (B. Wang et al., 2011). Moreover, after 
being activated, macrophages within tumors produce a variety of cytokines, growth 
factors, reactive oxygen species, proteases that modulate angiogenesis (Morgan et al., 
2004). While macrophage infiltration at high levels may be associated with poor 
cancer prognosis, little is known about the exact role of the distinct  pro- and 
antitumoral macrophages populations in cancer development (B. Wang et al., 2011). 
Therefore, defining and differentiating these subsets remains a challenging work in 
progress. Future studies in prostate cancer development that address the targeting 
macrophage plasticity necessary to mold an immunosuppressive population, the 
phenotypic heterogeneity of macrophages within tumors and their link in human 
prostate cancer will be advantageous. 
Macrophage Biomarker 
EGF-like module-containing mucin-like hormone receptor-like 1 (EMR1) and 
its mouse homologue, F4/80, are members of the G Protein-Coupled Receptors 
(GPCR) superfamily, subfamily EGF-TM7. The molecular weight of F4/80 
glycoprotein is approximately 160 kDa (Starkey, Turley, & Gordon, 1987). F4/80 is 
derived from mature B cell macrophage subpopulations such as splenic red pulp 
macrophages and microglia (Starkey et al., 1987). It is a transmembrane protein that 
is expressed on the cell surface of human macrophages (Gordon, Hamann, Lin, & 
Stacey, 2011). It is commonly used as a mature macrophage infiltration marker in 








Xenobiotics are considered foreign substances within a mammalian system. 
These particles include dietary agents, carcinogens, and other substances. Since 
organisms are constantly exposed to xenobiotics, adaptive mechanisms have evolved 
to assist with resolving those challenges. In higher eukaryotes this mechanism 
includes an increase in its metabolism and clearance in response to the detection of an 
insulting biological compound. Clearance of these materials has been linked to 
xenobiotic metabolizing enzymes. These enzymes are generally classified into three 
groups, which include Phase 1, Phase 2, and Phase 3. Cytochrome P450s are diverse 
set of genes that composes approximately 70-80% of Phase 1 enzymes and are 
considered the first line of metabolic defense. These enzymes are involved in the 
transformation of lipophilic compounds into water-soluble compounds as well as the 
activation of procarcinogens to the active, electrophilic, carcinogens that disrupt 
functioning by binding to the DNA of normal cells (W. E. Evans & Relling, 1999). 
Tightly regulated induction of Phase 1 and 2 enzymes in response to the level of 
xenobiotic exposures has been considered a key characteristic of these enzymes. 
Moreover, characteristic has been associated with the increased clearance of 
carcinogens and overall health improvement. Thus, P450 enzymes have a key role in 




Biomarkers for Phase 1 and 2 Xenobiotic Metabolism 
 
Functions of Phase 1 enzymes generally include catalyzing reactions to 
increase substrate hydrophilicity. This is done by introducing a functional group to 
modify the compound (G. Smith, Stubbins, Harries, & Wolf, 1998). In certain cases, 
xenobiotics including carcinogens may be activated during phase 1. However, these 
compounds may be further metabolized into less reactive products by Phase 2 redox-
related proteins including NQO1 and UGT1A1 (G. Smith et al., 1998). 
Cytochrome P450, family 1, member A1 (CYP1A1) is expressed 
predominately extrahepatically. One characteristic feature of CYP1A1 is that it has an 
aryl hydrocarbon receptor, which gives it the ability to bind to androgen receptors and 
nuclear factor- κβ. This binding capacity has an important role in carcinogenesis 
(Bassères & Baldwin, 2006; Currier et al., 2005). Cytochrome P450, family 1, 
member B1 (CYP1B1) is another well-studied xenobiotic metabolizing enzyme. 
However, some data suggests that certain CYP1B1 genotypes may have increased 
expression in patients with prostate cancer, in which single nucleotide point mutations 
were identified in cases of sporadic and hereditary prostate cancer cases. Differences 
in allele frequency as a result of these SNPs were marginally significant in the 
sporadic PCa cases than the control group (unaffected men) (Chang et al., 
2003).Cytochrome P450, family 2, member C9 (CYP2C9). Cytochrome P450, family 
3, member A4 (CYP3A4) may be considered one of the most important enzymes for 
drug metabolism as it accounts for approximately 50% of some currently utilized 




(Singh & Michael, 2009). Cytochrome P450, family 2, member D6 (CYP2D6) has 
been heavily studied for its role in metabolism anticancer drugs (Singh & Michael, 
2009). Taken together, these CYP enzymes and respective families are responsible 
for over 75% of metabolic actions with the human (Guengerich, 2008). 
Use of natural dietary compounds such as I3C and PEITC to regulate 
xenobiotics is a widely studied subject. Both dietary administered I3C and PEITC 
upregulate phase 1 and 2 enzymes to facilitate the modification and excretion of 
carcinogens and has been implicated in the promotion of tumor regression (T. T. 
Wang et al., 2012). Moreover, PEITC has also been shown to inhibit CYP450 activity 
involved in carcinogen (DBMA and MKK)-induced cancers (Morse et al., 1990).  
UDP glucoronosyltransferase 1 family, polypeptide A1 (UGT1A1) is an 
enzyme responsible for facilitating glucoronidation. Glucoronidation is a chemical 
process in which a glucoronic acid is conjugated to another substance, such as a 
modified carcinogen to aid with its excretion from the system. Moreover, 
glucoronidation is a main metabolic pathway for estrogen detoxification in the 
prostate and other steroid target tissues. Epidemiological and clinical studies assessed 
for associations between prostate cancer risk and UGT1A1 expression (Dalhoff, Buus 
Jensen, & Enghusen Poulsen, 2005; Karatzas et al., 2010; Tang et al., 2011). 
NAD(P)H dehydrogenase, quinone 1 (NQO1) is a FAD-binding protein that is 
responsible for reducing quinones to hydroquinones. The gene encoding for NQO1 is 
highly inducible. The enzymatic activity of this protein inhibits the electron reduction 
of quinones and subsequently, controls the formation of radical species (National 




and 2 xenobiotic metabolism genes have been associated with increased susceptibility 
of cancer (Cunningham et al., 2007; Zhou et al., 2009). NQO1’s role in the protection 
against reactive species contributes to cell stability by protecting against proteosomal 
degradation within the cell membrane (Dinkova-Kostova & Talalay, 2010). 
Treatment with I3C and PEITC has been shown to significantly increase 
hepatic NQO1 gene expression in mammals (Abdull Razis & Noor, 2013; Barve et 
al., 2008; Razis et al., 2012). Increased production of NQO1 has been shown to have 
protective antioxidant functions against toxic and neoplastic effects of carcinogens 
and against oxidative species (Dinkova-Kostova & Talalay, 2010).  
One overlapping theme with these Phase 1 and 2 xenobiotic metabolizing enzymes is 
the influence of genetic variation and correlation of the gene variants with prostate 
cancer (Chang et al., 2003; Zeigler-Johnson et al., 2004). 
Overall, understanding the impact of dietary phytochemicals such as I3C and 
PEITC on the activity levels of various xenobiotic enzymes plays an important role in 
determining the efficacy of treatment in all stages of cancer. From a cancer 
prevention perspective, modulating rates of xenobiotic enzymes by modifying intake 
of glucosinolate-derived compounds may help provide a barrier of protection against 
carcinogen exposure. 
Role of Aryl Hydrocarbon in I3C Metabolism 
The ligand-activated aryl hydrocarbon receptor (AhR) is a transcription factor 
within the basic helix-loop-helix-PER/ARNT/SIM homology (bHLH-PAS) 
family(Karchner et al., 1999). AhR receptor is known to regulate the induction of 




through a classical pathway (Denison & Nagy, 2003; Denison, Soshilov, He, 
DeGroot, & Zhao, 2011). Moreover, AhR may play a role in the interference of 
nuclear receptor-mediated proliferation. In a review published by Okey, 
polymorphisms in nuclear receptors can dramatically modify particular xenobiotic 
actions on gene expression and subsequent toxicity in laboratory animals and possibly 
humans (A.B. Okey, 2005). Polymorphisms in the AR have been characterized for 
their effects on physiologic function and for possible roles in resistance to hormonal 
cancer therapy (A. B. Okey et al., 2005). Classical AhR ligands and CYP1A1 
inducers are halogenated and polycyclic aromatic hydrocarbons such as 2, 3, 7, 8-
Tetrachlorodibenzo-p-dioxin (TCDD), benzo(a)pyrene (BAP), and β- 
naphthoflavone. Nonclassical, naturally occurring AhR inducers include dietary 
compounds including I3C and its metabolite, DIM, flavonoids, and curcumin, that 
may act as exogenous ligands. In addition to its actions on androgen receptor, I3C has 
shown to accelerate the metabolism of xenobiotics by inducing P450 enzymes and 
AR degradation in a nonclassical pathway (Denison & Nagy, 2003; Ramadoss, 
Marcus, & Perdew, 2005).  
Cell and Animal Model Used to Assess Prostate Cancer 
 
Some of the major challenges in prostate cancer research has evolved around 
1) the development of reliable screens that distinguish cancers that will remain 
indolent versus those that will become aggressive; and 2) to elucidate mechanisms 
that contribute to the prevention or control of disease progression. Laboratory and 




factors. With these models, precise manipulation of experimental conditions enables 
researchers to have better environmental control within the studies.  
Rodents are one of the most commonly used animals for laboratory research 
due to their relatively short life span, cost, and efficiency. Researchers are able to 
gather data in a comparatively fast manner in cancer studies through dynamic whole 
body system approaches that are suitable for a wide variety of tests. Moreover, in vivo 
studies, usually carried out in mice or rats, may depict how nutrients and other 
compounds affect various steps in the procession of cancer. Given limitations such as 
the reciprocal interpretations of rodent to human systems, the genetic similarity 
(~90%) still makes the use of rodents as ideal preclinical, laboratory models 
(Wiseman, 2008). 
Cell Models 
Prostate cancer cell models have been in use for decades. Classical models 
include LNCaP, DU145, and PC3. Early animal models of prostate cancer have 
suggested that prostate cancer, early in its development, is heterogenous and 
composed of both androgen-independent and androgen-dependent cells (Isaacs & 
Kyprianou, 1987; Kokontis, Hay, & Liao, 1998). Thus, there is a need for a wide 
variety of prostate cancer cell models in order to understanding the dynamic survival 
susceptibility of this disease. Suitable prostate cancer cell model with well-
characterized phenotypes. LNCaP, PC-3, and DU145 are among some of the most 
widely used human cell lines in basic and preclinical research.  
LNCaP cells are adherent, epithelial, human prostate cells were originally 




vitro assays and tumorigenic in immunologically deficient animals (J. L. Fisher et al., 
2002). Key characteristics of this cell line are its responsiveness to DHT and ability to 
stop cycling following the removal of androgen (Langeler, van Uffelen, Blankenstein, 
van Steenbrugge, & Mulder, 1993; Lim et al., 1993). Moreover, LNCaP contains a 
mutated androgen receptor, causing a point mutation (A-G) in codon 868 of a 910 
codon (or its equivalent position 877 of a 919 codon) AR cDNA, which transitions 
threonine into alanine (Newmark et al., 1992; Veldscholte et al., 1992). As a result of 
this change, ligand specificity is decreased, enabling the AR to respond to steroid 
hormones such as estrogen and progesterone in addition to androgen (Olea, Sakabe, 
Soto, & Sonnenschein, 1990). This cell is positive for androgen and estrogen 
receptors and treatment of this cell line with relatively low levels of estrogen and 
progesterone results in enhanced growth, even in the absence of androgen (Newmark 
et al., 1992; Olea et al., 1990). With the recognition of an AR mutation in the prostate 
cancer cell line, LNCaP, it became important to search for mutations in the AR that 
might enhance or alter its function.  
The C4-2 cells are derived from the LNCaP cells that were passaged in 
castrated mice. Since castration renders the mice, C4-2 cells are more invasive, less 
sensitive, and more characteristic of a human progressive prostate cancer with 
moderate tumorigenicity (Sobel & Sadar, 2005a, 2005b).  
The underlying mechanism for adaption to androgen-independent state is not 
known. However, cells that survive androgen depletion by any means are 
theoretically available to repopulate metastatically, or even in the prostate at later 




independence, androgen independent cell lines such as DU145 and more advanced, 
PC-3 cell lines are used. The androgen-independent PC-3 cells were isolated from a 
bone metastasis in a patient with castration-resistant prostate cancer (CRPC) and 
consequently display a high tumorigenic potential. DU145 is a hypotriploid human 
prostate carcinoma cell line with an absent N13, abnormal Y chromosome, and X 
chromosome that may be present in a single copy. Significant features of this 
epithelial cell line is that it forms grade II adenocarcinomas consistent with primary 
prostatic tumors in nude mice (Stone, Mickey, Wunderli, Mickey, & Paulson, 1978). 
Moreover, DU145 cells lines are reported to be hormone insensitive and do not 
express prostate antigen (Papsidero et al., 1981). It is an adherent cell with observed 
microvilli, tonofilaments as revealed in ultrastructural analyses and moderate 
metastastic capabilities (Stone et al., 1978). Interestingly, while DU145 and PC-3 
growth may be androgen-independent, both cell lines express the androgen receptor 
(Alimirah, Chen, Basrawala, Xin, & Choubey, 2006). 
Animal Models 
Genetic backgrounds of mice have been extensively studied. Its genome offers 
a high degree of homology with human counterparts, with greater than 99% of mouse 
genes being homologous to the human genome (Waterston et al., 2002).  
Xenograft models are mainstays for immontherapy research. In xenograft 
models, the inoculated tumor cells and the target organs are not from the same 
species, which may preclude the development or onset of carcinogenesis. However, 
these models allow for assessment of human cell lines at specific cancer stages, which 




variety of human prostate cancer cell lines may be used in the establishment of 
xenografts within immune deficient or SCID mice. Common mouse models used in 
the assessment of prostate cancer include BALB/c nu/nu, C5BL/6, NOD SCID, and 
TRAMP mice (Irshad & Abate-Shen, 2013; Shirai et al., 2000). 
The BALB/c nude mouse was originally developed in Japan by cross-breeding 
BALC/cABom-nu and BALB/cAnNCrj-nu. Notable characteristics in this mouse 
model include the absence of a thymus resulting in T-cell immunodeficiency, which 
makes this model an ideal hairless candidate for tumor biology and xenograft 
research. Average weight for these male mice species are approximately 15 g for 5 to 
22 g for 7 week old mice at the time of purchase and 25 to 28 g at 15 weeks in age for 
mice purchased in the U.S. (Charles River). 
The NOD SCID mice are another type of mouse model used in tumor biology 
and xenograft research. This white, albino mouse model have a SCID mutation. This 
mutation was transferred onto a non-obese diabetic background and have impaired T 
and B cell lymphocyte development (Ittmann et al., 2013). The mice model has also 
been reported to be deficient in natural killer (NK) cell function, which may explain 
why they have a slightly higher tumor implantation rate than Balb/c nude mice 
(Hensley & Kyprianou, 2012).  
C57BL/6 is a black haired mouse model that is considered a general purpose 
laboratory mouse. This model has been used in tumor xenograft studies, however, it is 
more commonly used in diet-induced obesity, transgenic/knockout model 




Genetically engineered mouse models have taken front stage in terms of 
prostate cancer research. The transgenic adenocarcinoma of the mouse prostate 
(TRAMP) is a model generated on a C57BL/6 background and is used in the 
assessment of prostate cancer. The pathogenesis of prostate cancer in this model 
resembles the progression of human prostate cancer (Ittmann et al., 2013). However, 
tumors exhibit increased levels of nuclear TRP53 and decreased androgen receptor 
expression (Ittmann et al., 2013). In this model, the prostate cancer spontaneously 
develops as a consequence of SV40 T antigen expression (Hurwitz, Foster, Allison, 
Greenberg, & Kwon, 2001).  
 
Expected timeline of prostate cancer is as follows: 
• By 12 weeks of age- exhibit prostatic epithelial neoplasia (PIN) 
• By 24 weeks of age- exhibit well differentiated adenocarcinomas; mostly located 
in the dorsal and lateral lobes of the prostate 
• By 30 weeks of age- exhibit evidence of metastatic spread to lymph nodes, lungs, 








Table 3 AIN-93M mature rodent diet formulation 
Diet  
  gm% kcal% 
Protein 14 15 
Carbohydrate 73 76 
Fat 4 9 
Total   100 
kcal/gm 3.8   
      
Ingredient gm kcal 
Casein 140 560 
L-Cystine 1.8 7.2 
      
Corn Starch 495.69 1982.8 
Maltodextrin 10 125 500 
Sucrose 100 400 
      
Cellulose, BW200 50 0 
      
Soybean Oil 40 360 




      
Mineral Mix S10022M 35 0 
      
Vitamin Mix V10037 10 40 
Choline Bitartrate 2.5 0 
      
      





Table 4 AIN-93M mature rodent diet with 0.1, 1, and 100 µmol indole-3-carbinol per 
gram diet 
Diet (µmol/g diet) 0.1 1 100 
  gm% kcal% gm% kcal% gm% kcal% 
Protein 14 15 14 15 14 15 
Carbohydrate 73 76 73 76 73 76 
Fat 4 9 4 9 4 9 
Total   100   100   100 
kcal/gm 3.8   3.8   3.8   
              
Ingredient gm kcal gm kcal gm kcal 
Casein 140 560 140 560 140 560 
L-Cystine 1.8 7.2 1.8 7.2 1.8 7.2 
              
Corn Starch 495.69 1982.8 495.69 1982.8 495.69 1982.8 
Maltodextrin 10 125 500 125 500 125 500 
Sucrose 100 400 100 400 100 400 
              
Cellulose, BW200 50 0 50 0 50 0 
              
Soybean Oil 40 360 40 360 40 360 
t-Butylhydroquinone 0.008 0 0.008 0 0.008 0 




Mineral Mix S10022M 35 0 35 0 35 0 
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Table 5 AIN-93M mature rodent diet with 5 µmol phenethyl isothiocyanate per gram 
diet 
Diet  
  gm% kcal% 
Protein 14 15 
Carbohydrate 73 76 
Fat 4 9 
Total   100 
kcal/gm 3.8   
      
Ingredient gm kcal 
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Corn Starch 495.69 1982.8 
Maltodextrin 10 125 500 
Sucrose 100 400 
      
Cellulose, BW200 50 0 
      
Soybean Oil 40 360 
t-Butylhydroquinone 0.008 0 




Mineral Mix S10022M 35 0 
      
Vitamin Mix V10037 10 40 
Choline Bitartrate 2.5 0 
      
2-Phenylethyl Isothiocyanate 0.816 0 
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